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1 Aims of the present thesis 
 
The surface of mammalian cells is covered by a dense layer of complex carbohydrates. 
collectively known as the “glycocalyx” or cell coat. These sugar structures represent 
potential targets for biorecognitive proteins such as lectins, which, by definition, possess 
at least one non-catalytic domain that binds reversibly to specific mono- or 
oligosaccharides. Thus, lectins can serve as tools to characterize the glycosylation 
pattern of cells, which can change during development, differentiation, and malignant 
transformation. To pursue this major task of the work, various plant lectins with 
different carbohydrate specificities were applied to the following cell lines: human 
bladder carcinoma 5637 cells, human chondrocytic C-28/I2 and T/C-28a2 cells as well as 
primary human chondrocytes, porcine PBMEC/C1-2 and human ECV304 cells mimicking 
the blood-brain barrier, and human THP-1 cells as model for human monocytes and 
macrophages. Concerning these cell models, another important aspect of the present 
work included the establishment of some of the above-mentioned cell lines and a 
detailed characterization, e.g. via immunofluorescent staining techniques.   
After evaluation of the bioadhesive properties of selected lectins and their binding 
specificity, ongoing focus was set on the mechanisms involved in uptake and intracellular 
fate of certain lectins being potentially useful as vehicles for lectin-mediated drug 
delivery. Further studies included the preparation of wheat germ agglutinin (WGA)-
functionalized nanoparticles which were applied to untreated and differentiated THP-1 
cells. 
Based on these studies, an estimation of the carbohydrate composition of the cell lines 
under investigation should be possible and the potential and feasibility of the lectin-
mediated targeting concept determinable. 
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2 Introduction 
 
The importance of carbohydrates, the most present type of biomolecules in nature and 
widely expressed as glycoproteins and glycolipids, is well documented for many 
important biological functions such as cell adhesion, cell-cell recognition, immunological 
response, inflammation, and proliferation [1-4]. They are major components of the outer 
surface of all mammalian cells building a dense layer which is called cell coat or 
glycocalyx. Diversity in glycosylation is found at every level of biological organization, 
between species, within populations of the same species, and also among different 
molecules and cell types within the same organism [5]. It has been shown that 
oligosaccharide structures change during development or differentiation, and abnormal 
glycosylation is associated with pathological conditions including malignant 
transformation [6]. Nevertheless, despite numerous efforts, the extent to which the 
sugar code – a term introduced by H.J. Gabius with a biological information content of 
1.44 x 1015 hexasaccharides [7] – has been decoded is still limited. A class of substances, 
which are capable of recognizing and binding carbohydrates, are lectins of both 
endogenous and exogenous origin. 
 
Lectins 
Definition 
Originally identified in plant extracts, lectins are nowadays known to be present in most 
organisms, ranging from viruses and bacteria to plants and animals [8]. They are 
considered as a large and heterogenous group of proteins or glycoproteins, which were 
initially defined as “carbohydrate-binding proteins of non-immune origin which 
agglutinate cells or precipate glycoconjugates” [9]. That way, some poorly or non-
agglutinating proteins were excluded, which were known to contain lectin subunits. 
Additionally, some lectins possess another binding site that interacts with non-
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carbohydrate ligands and thus, lectins were later defined as “carbohydrate-binding 
proteins other than antibodies and enzymes” [10]. Recently, to be classified as a lectin, a 
protein or glycoprotein has to meet the following criteria: 
1) A lectin is a (glyco)protein that binds carbohydrate.    
2) Lectins are separated from immunoglobulins. 
3) Lectins do not biochemically modify the carbohydrates which they bind [11]. 
As the present work concentrates on plant lectins as tools for glycan detection and 
vehicles for lectin-mediated drug targeting approaches, the definition of Peumans and 
Van Damme is used in the following papers: Plant lectins can be defined as all plant 
proteins that possess at least one noncatalytic domain that binds reversibly to a specific 
mono- or oligosaccharide [12].  
 
Occurrence and distribution 
The storage organs of plants are the richest source for plant lectins. In seeds, they 
typically represent 0.1-5% of the total protein content, but there are examples in some 
Phaseolus species in which lectins account for up to 50% [13]. Lectins were also isolated 
from roots (e.g., Phytolacca, Sambucus, Urtica), tubers or bulbs (e.g., Allium, Galanthus, 
Solanum), bark (e.g., Maackia, Robinia, Sambucus), leaves (e.g., Aloe, Lactuca, Viscum album), 
rhizomes, fruits, flowers, ovaries, phloem sap and nectar [11-13]. Lectins, which are 
found in seeds, are normally confined to them, but there are some legume lectins, which 
are additionally found in barks. Non-seed lectins can occur in different tissues of the 
same plant. The potato lectin, for instance, is found in tubers, stems, leaves, and fruits. 
An exception is the ground elder lectin, which is restricted to the rhizome [13]. The 
amount of lectin varies markedly among different plants. Canavalia ensiformis and Ricinus 
communis contain 2100 and 1400 mg lectin/100 g seeds, respectively, whereas for Ulex 
europaeus I only 16 mg lectin/100 g seeds are found. Other interesting lectins used 
within this work are Arachis hypogaea (190 mg/100 g seeds), Dolichus biflorus (110 mg/100 
g seeds), Lens culinaris (60 mg/100 g seeds), and Triticum vulgare (45 mg/100 g seeds) [11].  
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Carbohydrate specificity 
According to the ability of lectins to bind one or more monosaccharides, lectins were 
classified into five groups: mannose/glucose-, N-acetylglucosamine-, N-
acetylgalactosamine/galactosamine-, fucose-, and sialic acid-binding lectins [14]. Except 
for fucose, sugars are of D configuration. Other specificities are found rarely, as these 
sugars are also typical components of the surfaces of eurkaryotic cells. As an exception, 
the human serum amyloid P component, a lectin occuring in certain algal 
polysaccharides, in a marine sponge, and in a yeast, binds to 4,6-cyclic pyruvate acetal of 
galactose [8]. Lectins, which bind solely oligosaccharides are excluded from this 
classification (e.g., Griffonia simplicifolia IV, Phaseolus vulgaris). Thus, they are mostly 
regarded as lectins with a “complex specificity”. Interestingly, many plant lectins, which 
are able to bind monosaccharides, have a higher affinity for oligosaccharides, which are 
not common or even absent in plants [12]. For instance, lectins from elderberry 
(Sambucus sp.) and Maackia amurensis bind to a major carbohydrate constituent of animal 
glycoproteins absent in plants [12]. As an important consequence of the preference of 
plant lectins for sugar components from animal or microbial origin, most lectins seem to 
be aimed at foreign glycoconjugates rather than endogenous receptors Thus, plant 
lectins are regarded as useful tools for the isolation and analysis of human and animal 
glycoconjugates with impact on clinical applications [13].   
 
Lectin-carbohydrate interaction:  
Comparable to other carbohydrate-binding proteins, lectins combine with carbohydrates 
primarily via a network of hydrogen bonds and hydrophobic interactions. In some cases, 
electrostatic interactions and coordination with metal ions are also involved [8]. 
Hydrogen bonds are formed between the hydroxyl groups of the carbohydrate and the 
amino side chains of the lectin, frequently including aspartic acid, glutamic acid, glutamine 
and araginine residues. Occasionally also hydroxyl side chains of the protein are involved 
[15]. 
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Moreover, van der Waals interactions being commonly present may contribute 
significantly to binding, though usually characterized as rather weak forces. The steric 
disposition of the hydroxyl groups of carbohydrates normally representing hydrophilic 
molecules can result in creation of hydrophobic patches on the sugar surfaces which 
then forms contacts with hydrophobic side chains of the protein [8]. For example, a 
methyl group of N-acetylamino sugars may interact with aromatic residues in lectins [8]. 
Ionic interactions occur rarely as they require charged molecules, and saccharides are 
mostly uncharged. An exception is the bond between a histidine of the cation-dependent 
Man6P receptor and the phosphate of Man6P [15].  
Water has the ability to serve as hydrogen donor as well as acceptor. That way water 
can mediate a lectin-carbohydrate interaction by forming bridges, which commonly 
consist of a single water molecule [15].   
Due to the binding capacity of lectins to carbohydrates of the cell surface, they might be 
used as carrier molecules to target drugs specifically to particular cells and tissues. In this 
context, two approaches are followed to date: the prodrug-concept as represented by 
soluble lectin-drug conjugates and surface modified carrier systems [16]. For both drug 
delivery systems, besides cytoadhesion, cytoinvasion of the lectin is desirable. Uptake of 
different lectins has been observed in various studies, for instance for tomato lectin 
found to be transported across the intestinal epithelium [17, 18], for peanut agglutinin 
located in peripheral venous blood after oral administration [19]. Transcytosis of Ulex 
europaeus agglutinin-I was assessed after binding to mouse M-cells [20]. Thus, 
complementing the evaluation of lectins for drug delivery purposes, the cytoinvasive 
potential of selected lectins was assessed during this thesis.  
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Application and function of lectins: 
Some fields of application for lectins were already mentioned above. A recent summary 
was given by Gabius et al [21]:  
Table I: Plant lectins as research tool, 
taken from   [21] 
 
 
 
 
 
 
 
 
 
 
 
 
 
Despite the various options for the use of lectins, their physiological role is often 
discussed controversially. Again, Gabius et al have recently compiled a summary as 
shown in Table II. 
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Table  II: 
Physiological role 
of plant lectins, 
taken from [21] 
  
 
 
 
 
 
Lectins used in the following studies 
To cover a broad range of possible carbohydrate structures at the cell surface, lectins 
with distinct specificities were chosen as follows:  
Wheat germ agglutinin (WGA), Solanum tuberosum lectin (STL), Lens culinaris agglutinin 
(LCA), Ulex europaeus isoagglutinin I (UEA-I), Sambucus nigra agglutinin (SNA), Dolichus 
biflorus agglutinin (DBA), and peanut agglutinin (PNA).  
Each lectin is characterized in detail in Table III.  
 
Table III: Plant lectins used in the following studies. 
 
Lectin 
 
MW 
 
    Carbohydrate specificity 
 
Structure 
 
WGA 36 000 GlcNAc, sialic acid 
dimeric carbohydrate free protein of 2 identical 
subunits, which contain four repetitive domains; 
mixture of 3 isoforms 
STL   100  000 GlcNAc 
dimeric protein of 2 identical subunits, which 
contain up to 40-50% covalently linked carbo- 
hydrate;  
PNA 110 000 
ß-D-Gal-D-GalNAc, ß-D-
GalNAc, Gal 
homotetrameric non-glycosylated protein of 4 
subunits; complex mixture of isolectins 
DBA 120 000 α-D-GalNAc, Gal heterotetrameric glycoprotein 
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UEA 63 000 α-L-Fuc 
dimeric glycoprotein of 2 different subunits; 
isolectin I 
SNA 150 000 Sialic acid α(2,6)Gal/GalNAc 
glycoprotein of 4 units [A-s-s-B]; 
isolectin I 
LCA 49 000 α-Man, α-Glc, α-GlcNAc 
protein composed of 2 α-chains and 2 ß-chains; 
mixture of 2 isoforms  
GlcNac, N-acteyl-D-glucosamine; α-Glc, α-glucose; α-D-GalNAc, N-acetyl-α-galactosamine; Gal, galactose; α-L-Fuc, α-L-fucose;  
α-Man, α-mannose;   
 
 
Cell cultures 
As already mentioned above, the present work focuses on the application of lectins to 
characterize the glycosylation pattern of different cell types, in order to compare the 
glycosylation profiles, to detect alterations in the glycocalyx during differentiation of 
cells, to follow cytoinvasion of selected lectins, and to provide thereby a suitable basis 
for lectin-mediated drug delivery approaches. To accomplish these goals, the following 
cell lines were used during this work: 
5637 cells as model for human bladder carcinoma, 
C-28/I2, T/C-28a2, and primary human chondrocytes for cartilage research, 
PBMEC/C1-2 and ECV 304 cells for characterization of the blood-brain barrier, and 
THP-1 cells as model for human monocytes which undergo differentiation to 
macrophages.  
In general, cell cultures play an important role in the first stages of pharmaceutical 
development. They can be applied for numerous purposes including studies on cell 
physiology, metabolism, protein expression, and they represent tools for analysis of 
active and passive transport of drugs, for toxicity tests, and for the development of 
specific delivery systems. In contrast to animal models, which have been in use for a long 
time to evaluate biopharmaceutical characteristics of new pharmaceutical ingredients but 
with clear limitations due to divergent species specificities, the complex nature of the 
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model as well as ethical reasons, cell culture models offer the advantage of being a 
defined system in which parameters and conditions can be changed as required. 
Nevertheless, for a precise handling and accurate interpretation of results, a detailed 
characterization and reliable standardization is essential. In this context, another 
important aspect of the present work was set on the establishment of some of the 
above-mentioned cell lines including a careful characterization using for example 
immunofluorescent staining techniques.  
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3 Specific topics 
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Part I: bladder 
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Abstract 
Bladder cancer is the ninth most common malignancy in the world featuring a very high 
gender variability in occurrence. Current options for bladder cancer therapy include 
surgery, immunotherapy, chemotherapy, and radiotherapy with a trend towards 
multimodal treatments. However, successful management remains a challenge for 
urologists and oncologists due to the high risk for recurrence and progression. Especially 
in the field of bladder cancer chemotherapy, efficacy of treatment might be improved by 
advanced drug delivery strategies aiming at prolonged residence time within the bladder 
cavity and increased permeability of the bladder wall during intravesical instillation. 
Moreover, a deeper understanding of the biology of bladder carcinogenesis and 
progression stimulated the development of a new generation of anti-cancer drugs for 
targeted therapies which might result in an increased treatment specificity together with a 
lower toxic potential and higher therapeutic indices. The present review will discuss the 
currently available strategies for “targeted therapy” focusing on molecular targets and for 
“controlled delivery” comprising all other approaches towards improved drug delivery. 
 
 
 
 
 
Keywords: bladder cancer; chemotherapy; controlled delivery; drug targeting; 
intravesical delivery; targeted therapy; urothelial cell carcinoma 
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1. Introduction 
Recent literature ranks bladder cancer as the ninth most common malignancy worldwide 
together with a very high gender variability in occurrence [1]. Interestingly the incidence 
of bladder cancer varies significantly among countries with highest rates in the Western 
world. Particularly high incidence rates were observed for Southern Europe, Northern 
Africa, North America and Western Europe; occurrence in Asian countries is rather low 
[2]. In the USA, bladder cancer is the fourth most common cancer diagnosed in males 
with estimated 51,230 new cases and 9,950 deaths from bladder cancer in 2008 [3] The 
two most well established risk factors for bladder tumour include cigarette smoking and 
occupational exposures to urothelial carcinogens. In addition, other environmental 
exposures like chronic urinary tract infections, cyclophosphamide use, schistosomiasis, 
and exposure to radiotherapy as well as inadequate consumption of fruits, vegetables, and 
certain vitamins may be associated with risk of bladder cancer. Even coffee consumption 
and artificial sweeteners are discussed to have an impact on tumorigenesis, while familial 
bladder cancer is fairly rare as compared to other tumour sites [4]. 
In general, bladder cancer is a rather heterogeneous disease making classification, staging 
and grading a challenging task. On average, 70% of bladder urothelial cell carcinomas 
represent a superficial disease and the remainder develops a muscle-invasive disease 
bearing the risk of metastatic spread of the tumour [5]. Standard treatment for superficial, 
non muscle-invasive bladder cancer is complete transurethral resection and subsequent 
cystoscopic surveillance. However, the major challenge in the management of superficial 
bladder cancer is not the removal of a lesion once present but rather the prevention of 
tumour recurrence and progression. Thus, intravesical instillation of chemotherapeutic or 
immunotherapeutic agents is applied to reduce the risk for recurrence and to delay or 
even prevent progression to a muscle-invasive disease. Independent of the modality of 
treatment, two-thirds of patients diagnosed with superficial bladder cancer suffer from a 
recurrence of their tumour and 10–20% of those that recur demonstrate progression to 
muscle-invasive disease [6]. A tumour that has grown beyond the lamina propria and 
invades the muscularis propria is usually treated with radical cystectomy. Radical surgery 
 
1 Aims/2 Introduction/3 Specific topics/4 Conclusion/5 Appendix 
 
 
 
 
Part I: bladder 
 
 
 32 
in the case of muscle-invasive bladder cancer therapy is usually accompanied by 
perioperative systemic chemotherapy to minimize metastatic dissemination and to 
improve survival of patients. For patients with disseminated disease aggressive systemic 
therapy with multiple chemotherapeutics is essential [7].  
Especially in the field of cancer chemotherapy the urgent need for improved drug 
delivery by directing the active pharmaceutical ingredient (API) to the diseased tissue 
stimulates the research efforts of pharmaceutical technologists since more than one 
decade. That way, due to their severe side-effects, the dose-limited effectiveness of 
conventional anti-cancer drugs might be overcome [8]. Improving drug delivery by 
guiding the drug to the desirable site of action is also a relevant issue in anti-cancer 
therapy of the bladder. Due to its unique anatomical and physiological properties the 
urinary bladder is ideally suited for minimally invasive intravesical therapy, an option 
that is widely used in the treatment of urothelial cancer at the superficial stage. However, 
despite the fairly easy access by instillation, intravesical delivery of effective 
concentrations still remains a challenge. The primary goal in intravesical drug 
administration is to maximize the exposure of the tumour to the therapeutic agent while 
limiting toxicity to the host. Due to the barrier function of the urothelium absorption of 
the API into the systemic circulation is limited avoiding overall toxicity, but the low 
residence time of a drug in the bladder, which rarely lasts beyond the first void, requires 
advanced and intelligent approaches towards sustained delivery in order to achieve 
efficacious drug concentrations within the bladder cavity. Representing one of the 
toughest barriers in the human organism [9], the transport across the urothelium occurs 
only via passive diffusion. Thus, improving the permeability of the bladder epithelium as 
well as increasing the concentration gradient between the urine and the target site is 
expected to enhance drug penetration into the diseased tissue. Besides some more general 
physiological approaches, interesting methods in bladder cancer therapy comprise 
chemical agents that alter the urothelial permeability as well as device-assisted therapies, 
such as electromotive drug administration or thermo-chemotherapy. A prolonged 
residence time of the API in the bladder is achieved via several sustained drug delivery 
concepts including thermosensitive hydrogel formation in situ, mucoadhesion, 
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magnetically targeted carriers, and drug carriers from the nanotech pipeline such as 
liposomes, micro- or nanoparticles. Moreover, photodynamic therapy is employed in 
bladder cancer treatment.  
Recent knowledge of the molecular mechanisms underlying bladder carcinogenesis as 
well as tumour progression and response led to a further approach in bladder cancer 
therapy that is fundamentally different to the others mentioned and relies on molecular 
targeting of tumour relevant signalling pathways, cell cycle regulators, and specific 
receptors that are overexpressed at the tumour cell surface. Promising molecular targets 
in bladder cancer therapy include the epithelial growth factor receptor family, the Ras 
and phosphatidylinositol-3-kinase signalling pathway, cyclin-dependent kinases, and 
several others. The expected benefits of molecularly targeted therapies rely on a lower 
overall toxicity due to an increase in selectivity of the therapeutic agent. Moreover, the 
greater specificity might also show promise for successful therapy of advanced or 
metastatic disease. Further concepts in targeted bladder cancer treatment are based on 
gene therapy. Amongst others, potential targets in this area are the tumour suppressor 
gene p53, telomerase reverse transcriptase, and the apoptosis modulator bcl-2. Besides, 
an interesting focus of recent research deals with the prevention of metastatic spreading 
by the inhibition of neo-angiogenesis particularly in the management of advanced 
bladder cancer. In addition, glycotargeting via lectins might prove to be a promising 
alternative approach to selectively target malignant cells of the bladder. 
Below, the term “targeted” will be used primarily for molecular targeting, while 
“controlled” will be used for all others methods of improved drug delivery. 
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2. Controlled delivery  
Bladder tumours at a superficial stage are currently treated by transurethral resection 
followed by adjuvant instillation of chemotherapeutics or immunotherapeutics to lower 
the risk of recurrence and progression to muscle-invasive disease. For chemotherapy 
usually mitomycin C (MMC) and epirubicin are applied either as a single immediate 
instillation or multiple delayed instillations depending on the patient´s risk evaluation. 
Intravesical immunotherapy is predominantly done with bacillus Calmette-Guérin 
(BCG), an attenuated mycobacterium known as a potent inducer of passive immunity 
which is the best choice for high-risk patients even though local and systemic side-effects 
are more frequent and more severe than with intravesical chemotherapy [10]. Gold-
standard therapy in case of muscle-invasive bladder cancer relies on radical cystectomy 
usually in conjunction with perioperative systemic chemotherapy using a combination of 
methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) which proved to be 
substantially more effective than any single drug regimen [11,12]. M-VAC therapy is 
also a typical regimen for the treatment of metastatic carcinoma of the urothelium [13]. 
Moreover, a multi-drug combination chemotherapy using cisplatin, methotrexate, 
vinblastine (CMV) is applied in case of metastatic bladder cancer [14].  
Besides approaches relying on new chemotherapeutic agents and regimens [15] 
improvements in drug delivery have been in the focus of recent research in order to 
enhance the efficacy of bladder cancer therapy. Among the variety of efforts in this field, 
which will be discussed in detail below, there are also some general aspects in terms of 
the physiological status and function of the kidney and the bladder. These parameters 
include urine factors such as the residual volume in the bladder and the continuous urine 
production rate during intravesical treatment both resulting in dilution of the drug 
administered within the instillation fluid. A clever strategy to circumvent these problems 
is based on complete emptying of the bladder prior to dose administration as well as 
limited fluid intake by the patient prior and after instillation. In addition, the dosing 
volume and the dwell time are perceptible parameters, but their impact is lower [16]. 
Moreover, pH might be an issue depending of the chemotherapeutic agent in use. For 
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MMC rapid degradation in acidic environment could be avoided by alkalinizing the urine 
by oral administration of sodium bicarbonate. Together with an increased dosage of the 
cytostatic agent, a decrease of the instillation volume and considering the above 
mentioned parameters the efficacy of MMC treatment could be statistically significantly 
enhanced in a randomised phase III trial [17]. Another crucial point in intravesical 
chemotherapy is the vehicle used for drug administration. According to Groos et al. [18] 
sterile water might be a better diluent than saline due to the fact that osmolality was 
inversely correlated to the toxicity of chemotherapeutical agents in cell cultures. 
However, the residence time of the API at the site of action is a further decisive 
parameter often limiting efficient cancer treatment. A simple and reasonable way towards 
increased drug delivery to the bladder epithelium is prolonged instillation, but also more 
advanced approaches have already been pursued as follows.  
 
2.1. Thermosensitive Hydrogels 
To extend the residence time of the API in the bladder beyond the first voiding of urine 
postinstillation, the application of a thermosensitive hydrogel forming a drug depot inside 
the baldder cavity was proposed by Tyagi et al. [19]. Developed by Jeong et al. [20], the 
aqueous solution of the triblock co-polmyer PEG-PLGA-PEG (Polyethylene glycol-
poly[lactic acid co-glycolic acid]-polyethylene glycol) is fluid at room temperature and 
converts to a gel at body temperature. Using rat bladders and a modified thermogel, 
Tyagi et al. [19] reported a sustained release up to 24 h provided by the thermosensitive 
hydrogel which attaches itself as a smooth layer on the inner surface of the bladder and 
acts as a drug-loaded matrix. Although representing a promising approach, human data 
are not available yet.  
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2.2 Mucoadhesion 
Another approach to enhance drug transport is the concept of bioadhesion to the mucosal 
urothelium. This is the process whereby natural or synthetic macromolecules adhere to 
mucosal surfaces in the body and, when incorporated into pharmaceutical formulations, 
absorption of drugs can be enhanced due to prolonged exposure, shortening of the 
diffusional pathway and increasing the concentration gradient from the lumen to the cell. 
For chitosan and polycarbophil, permeation enhancement across the bladder wall has 
been assessed in previous studies on porcine bladders [21,22]. For specific post-operative 
chemotherapy, MMC loaded chitosan and alginate carriers were prepared by Oztürk et 
al. [23] which proved successful in mice. Lee et al. [24] investigated the effect of 
formulations with paclitaxel and glyceryl monooleate in a rabbit model of bladder cancer. 
They observed an increased bioadhesiveness to bladder mucosa providing a step forward 
towards targeting the bladder tissue. Ongoing studies focus on increased efficiency of 
drug absorption by API-incorporation into liposomes, micro- and nanoparticles with 
bioadhesive characteristics as discussed below. 
 
2.3. Drug carrier systems 
Liposomes 
Liposomes are artificial vesicles of spherical shape containing an aqueous core 
surrounded by one or more phospholipid layers. Thus, liposomes can be used as carrier 
systems for either hydrophilic or lipophilic compounds and can therefore alter 
pharmacologic and pharmacokinetic parameters of the transported drug. In a fundamental 
study Johnson et al. [25] determined whether liposomes can bind to human bladder 
cancer cells. Binding to tumor cells was saturable and appeared to be specific as binding 
of liposomes to normal fetal bladder cells was negligible. Thus, they might be a vehicle 
to improve the delivery of anticancer drugs. Vail et al. [26] encapsulated doxorubicin in 
polyethylene glycol-coated liposomes and showed in animal models an increased 
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potency over conventional doxorubicin as well as remission and cure of many cancers 
including the bladder. Anti-tumor effects of liposome-encapsulated titanium dioxide in 
bladder cancer treatment were examined by Chihara et al [27] in nude mice and revealed 
higher anti-tumour effects than non-coated titanium oxide. A recent study was performed 
by Humhuan et al. [28] who incorporated the BCG cell wall into cationic liposomes and 
demonstrated their uptake into murine bladder tumor cells.  
 
Micro- and Nanoparticles 
Polymeric micro- and nanoparticles have become widely applied as effective drug 
delivery systems. To prolong the residence time of paclitaxel in the bladder and to 
achieve controlled release, bio-adhesive poly(methylidene malonate-2.1.2) microspheres 
were prepared by Le Visage et al. [29], which were applied to Balb/c mice after N-butyl-
N(4-hydroxybutyl)nitrosamine (BBN)-induction of bladder cancer and compared to 
paclitaxel. After bladder instillation, microspheres adhered to the mucosa, remained in 
the bladder for up to 48 h and the 9-week survival rate was significantly improved. Lu et 
al. [30] developed paclitaxel-loaded gelatin-nanoparticles that rapidly released 
paclitaxel, yielded significant activity against human bladder cancer cells and showed 
higher tissue concentration as compared to commercial Cremophor®/EtOH formulations. 
Paclitaxel was also loaded in PLGA nanospheres to increase both efficiency and safety of 
the drug as well as to improve targeting [31]: Tested on thyroid, breast and bladder 
cancer cell lines these nanospheres showed a prolonged drug release and an increase of 
the cytotoxic effect with respect to free paclitaxel in all cell lines. Recently, paclitaxel 
was incorporated in nanoparticles made from hydrophobically derivatized 
hyperbranched polyglycerols. Their evaluation in nude mice with orthotopic KU7-luc 
tumors [32] revealed that HPG-C10-polyethylenglycol of paclitaxel was significantly 
more effective in reduction of tumour growth than paclitaxel formulated in Cremophor®. 
Another recently published study concentrates on the delivery of MMC encapsulated in 
cationic nanoparticles of chitosan and polycaprolactone [33]. Nanoparticles of poly-ε-
caprolactone coated with chitosan turned out to be an efficient formulation for a complete 
drug release and specific uptake by MB49 bladder carcinoma cells in contrast to normal 
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bladder cells. Recently, carbon nanotubes (CNTs) turned out to be a feasible carrier for 
carboplatin [34] as cell growth of human bladder cancer cells was inhibited in 
comparison to unfilled CNTs. 
Anchoring of antibodies, lectins, etc. on the surface of liposomes or micro- and 
nanospheres can further improve the site specificity of drug carriers and will be discussed 
in detail in section 3. 
 
2.4. Permeation enhancement: Chemical Approaches 
Dimethyl sulfoxide (DMSO) is a chemical compound with the distinct capability to 
penetrate tissues. Co-administration of DMSO proved to enhance the penetration of 
cisplatin in the urinary bladder of dogs [35], and improved the absorption of doxorubicin 
[36], pirarubicin [37], and epirubicin [38] in rat models. DMSO also reversed the 
entrapment of paclitaxel in Cremophor micelles, which is a commercial available 
formulation (i.e., Taxol®). Summarising all the effects, co-administration with DMSO 
resulted in increased delivery of paclitaxel to bladder tissue of dogs [39]. 
Sasaki et al. [40] evaluated the effects of a certain saponin on absorption of 4`-O-
tetrahydropyranyldoxorubicin (THP) through the bladder mucosa of rats. As the results 
revealed increased concentrations of THP in bladder tissue without affecting that in 
plasma, co-administration could be useful for intravesical chemotherapy. 
Hyaluronidase, an enzyme that degrades hyaluronic acid representing a major constituent 
of the extracellular matrix, had been administered to improve drug diffusion of cisplatin 
in 33 patients with superficial transitional bladder cell carcinoma [41]. Higher clinical 
efficacy over cisplatin alone was not detected, but a further study revealed a decrease in 
tumor recurrence after co-administration of MMC with hyaluronidase [42] in a 
randomized trial with 2 groups of 28 patients with highest significance (p < 0.05). This 
finding was verified in comparative studies with 43 patients treated with MMC and 
hyaluronidase (recurrence rate 7%) and 63 patients with MMC alone (recurrence rate 
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32%) [43]. Nevertheless, the feasibility of this concept has to be carefully evaluated since 
hyaluronidase can either act as tumor suppressor or promoter depending on cell type and 
concentration [44,45]. 
 
2.5. Permeation enhancement: Physical Approaches - Device-assisted therapy  
Electromotive drug administration (EMDA) 
The technique of electromotive drug administration is known to increase penetration of 
drugs through the urothelial barrier of the bladder after intravesical instillation by the use 
of an electric source. Based on the active principles of iontophoresis, electroosmosis and 
electroporation the transport of water-soluble drugs is enhanced and is most effective for 
ionized molecules where the rate of drug transport is proportional to the intensity of the 
applied current [46,47].  
In the treatment of bladder cancer a recent study was conducted by Colombo et al. [48] 
with patients suffering from single, recurrent, low stage, low grade superficial bladder 
tumour. 36 patients were treated with the standard procedure administering MMC as 
intravesical instillation, for 15 patients MMC was applied according to the electromotive 
procedure and in 29 patients MMC was administered in combination with local 
microwave-induced hyperthermia. Complete response was identified in 27.7%, 40% and 
66% of patients, respectively. For high-risk superficial bladder cancer Di Stasi et al. [49] 
assessed the efficacy of intravesical electromotive versus passive MMC using BCG as a 
comparative treatment in 108 patients. After 6 months follow-up, the complete response 
for electromotive vs passive MMC was 56% vs 31%, for BCG 64%. Local and systemic 
side effects were significantly more frequent in the BCG arm, leading to the suggestion 
that electromotive MMC may be an alternative therapy. In a randomised trial with 212 
patients with stage pT1 bladder cancer, the same authors compared the efficacy of 
sequential BCG and electromotive MMC with that of BCG alone [50]. After a median 
follow-up of 88 months, more patients assigned sequential BCG and electromotive MMC 
were disease-free (57.9 % vs 41.9%), higher disease-free intervals were achieved (69 
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months vs 21 months), progression rate was lower (21.9% vs 9.3%) and the overall (34% 
vs 21.5%) as well as disease-specific mortality (16.2% vs 5.6%)) was lower as compared 
to BCG alone.  
 
Hyperthermia 
Recently, intravesical hyperthermia was applied to improve the efficacy of 
chemotherapeutics termed as thermo-chemotherapy. Colombo et al. [51] developed the 
Synergo® system (Medical Enterprises Ltd, Amsterdam, The Netherlands) which 
consists of a 915 MHz intravesical microwave applicator, inserted through a catheter, 
that provokes hyperthermia of the bladder wall via direct irradiation. The bladder wall 
temperature is monitored by thermocouples located inside the catheter (goal temperature 
42-43°C) and a small peristaltic pump circulates the chemotherapeutic solution between 
the bladder and a drug reservoir. The efficacy of hyperthermia in combination with 
MMC versus MMC alone was evaluated in several clinical studies [52-54] and revealed 
to be more effective than intravesical chemotherapy alone for the treatment of superficial 
transitional cell carcinoma. A comprehensive study with 90 patients suffering from 
intermediate or high risk superficial transitional cell carcinoma was performed by Van 
der Heijden et al. [55]. After 2 years of follow-up the risk of recurrence was 24.6 % and 
no progression in stage and grade was observed. A current study from Witjes et al. [56] 
evaluated the potential of thermo-chemotherapy in 57 patients with mostly BCG 
refractory carcinoma in situ. A complete response rate of 94% was achieved with a 
recurrence rate of 30% at 1 year follow-up.  
 
2.6. Photodynamic therapy  
Photodynamic therapy (PDT) is a potentially selective approach for treating bladder 
cancer based on the interaction between a photosensitising agent in the target tissue and 
an intravesical light source to cause tissue necrosis. Using 5-aminolevulinic acid (5-
ALA) as a precursor of the potent photosensitiser protoporphyrin IX, a first clinical 
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experience for treatment of superficial bladder cancer was achieved by Kriegmair et al. 
[57]. After 10-12 weeks, 4 out of 10 patients had a complete and 2 partial remission, no 
change was detected for 3 patients and 1 suffered from progressive disease. Additionally, 
no serious side-effects were assessed. The same authors evaluated the efficacy of 
photodynamic therapy after oral administration of 5-ALA in 24 patients with superficial 
bladder cancer [58]. At a median follow-up of 36 months, 3 of 5 patients with carcinoma 
in situ and 4 of 19 patients with papillary tumours were free of recurrence. 3 patients 
were rendered disease-free by repeated therapy and 3 underwent cystectomy. But 
hemodynamic side effects such as hypotension and tachycardia, especially in patients 
with cardiovascular co-morbidity, must be taken into account. Thus, efficacy and side 
effects of PDT with intravesical application of 5-ALA were evaluated again by Berger et 
al. [59] with 31 patients suffering from recurrent superficial bladder cancer. 16 patients 
were recurrence free after an average follow-up of 23.7 months and therapy was well 
tolerated. The only side effects observed were dysuria and haematuria in 4 and 7 patients, 
respectively. Evidence for increased susceptibility of bladder cancer cells to 
chemotherapeutic agents after sequential administration of MMC and PDT was given by 
French et al. [60] in a preclinical study. In an ongoing phase-1 study with 24 patients 
with recurrent superficial bladder cancer, Skyrme et al. [61] assessed the potential and 
tolerability of ALA-PDT in association with MMC and found out that this procedure is 
safe, well-tolerated and able to manage difficult-to-control superficial transitional cell 
carcinoma and carcinoma in situ of the bladder. Improvements are in progress, on the one 
hand concentrating on newer generations of photosensitisers such as hypericin [62,63], 
on the other hand on novel targets such as the transferrin receptor for more specific 
therapy [64] or p38α MAPK inhibition to avoid tumour survival and recurrence [65].  
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3. Targeted therapy  
Whereas controlled delivery focuses on improving the overall drug exposure to the 
bladder, targeted therapies are selectively directed to cancer cells or the processes 
involved in their genesis and metastasis. Tumorigenesis is a multistep process that 
transforms normal human cells into malignant derivates. Among these steps, self-
sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of 
programmed cell death, unlimited replicative potential, sustained neo-angiogenesis, and 
tissue invasion and metastasis are regarded as essential alterations towards malignant 
growth [66]. The improved understanding of the biology of bladder carcinogenesis and 
tumor progression has led to the identification of specific genetic lesions as well as 
biochemical receptors and signal transduction pathways which should improve cancer 
diagnostics and can also serve as novel therapeutic targets. 
 
3.1. Epidermal growth factor receptor (EGFR) family 
The epidermal growth factor receptor family comprises four homologue receptors: ErbB1 
(EGFR, HER1), ErbB2 (HER2/neu), ErbB3 (HER3), and ErbB4 (HER4). They are 
composed of an extracellular binding domain, a transmembrane lipophilic segment, and 
an intracellular tyrosine kinase domain. Activation plays a crucial role in many cell 
regulatory processes such as proliferation, migration, and modulation of apoptosis 
leading to the progression of many malignancies including bladder cancer [67,68].  
 
Epidermal growth factor receptor (HER-1) 
The epidermal growth factor receptor (EGFR) is a 170 kDa transmembrane protein, 
which is normally expressed only on the basal layer of bladder epithelial cells. Upon 
malignant transformation EGFR is also highly expressed in the superficial layers of 
tumors and overexpression is detected in 31-48% of bladder cancer associated with 
progression of the tumor and a poor prognosis [69-72]. Being identified as a potential 
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molecular target, two major approaches are followed: monoclonal antibodies directed at 
the extracellular domain of the receptor and inhibition of the receptor´s tyrosine kinase.  
Regarding monoclonal antibody therapy, a promising candidate is IMC-C225/cetuximab 
(Erbitux®), a human/murine chimeric monoclonal antibody against EGFR. Perrotte et al. 
[73] showed in nude mice with metastatic human transitional bladder cancer that therapy 
with cetuximab had a significant antitumor effect, which was partially mediated by 
inhibition of angiogenesis. A study conducted by the same authors [74] further 
investigated whether the combination with paclitaxel could enhance this therapeutic 
effect. Again, this treatment down-regulated the expression of basic fibroblast growth 
factor, vascular endothelial cell growth factor, interleukin-8, and matrix 
metalloproteinase type 9 and inhibited tumor-induced neovascularisation compared with 
untreated control (p<0.005). This combination also enhanced apoptosis in tumour and 
endothelial cells as compared with drug alone (p<0.005). Current data of clinical studies 
with cetuximab in combination with chemotherapy are available for treatment of head 
and neck cancer [75], non-small cell lung cancer [76], and colorectal carcinoma [77]. For 
bladder cancer a phase II randomized trial evaluating the effects of gemcitabine and 
cisplatin with or without cetuximab is currently recruiting participants [78].  
ZD 1839/gefitinib (Iressa®) is an orally active EGFR tyrosine kinase inhibitor (TKI) that 
interacts with the intracellular tyrosine kinase domain and subsequently inhibits 
downstream signalling [79]. A basis for the application in bladder cancer treatment was 
provided from Nutt [80] and Dominguez-Escrig [81] who studied the therapeutic 
potential in preclinical bladder cancer models and evaluated the therapeutic value. In a 
phase II clinical trial, gefitinib has been tested in combination with cisplatin and 
gemcitabine in 27 untreated advanced transitional cell carcinoma patients [82]. In 
summary, the trial showed activity in advanced transitional cell carcinoma, but the 
relative contribution of gefitinib was not assignable and this regimen was associated with 
excessive toxicity. Currently, a randomised phase II study is being conducted for further 
evaluation [78].  
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In contrast to gefitinib, where the U.S. Food and Drug Administration (FDA) has 
restricted the use in advanced non-small cell lung cancer to patients participating in a 
clinical trial or continuing to benefit from treatment already initiated, OSI-774/erlotinib 
(Tarceva®), another small molecule TKI, is approved by the FDA for therapy of 
advanced non-small cell lung cancer and is continued to be investigated [83]. Associating 
this concept with bladder cancer, Yang et al. [84] assessed the effects of erlotinib in 
comparison to interferon-α on bladder cancer cell lines. Both, erlotinib and interferon-α 
were significantly antiproliferative, and combined treatment enhanced the sensitivity of 
most cell lines. Another study evaluated the epidermal growth factor receptor status of 
bladder carcinoma cells and the response to erlotinib [85] which demonstrated that even 
in absence of receptor mutations erlotinib showed potential as a therapeutic agent.  
 
HER2/neu  
HER2/neu is another transmembrane tyrosine kinase growth factor receptor which is 
overexpressed in urinary bladder carcinoma. In contrast to breast carcinoma, where HER-
2/neu gene amplification and receptor overexpression could be correlated and had 
prognostic and therapeutic values, varying results have been reported for bladder cancer, 
and the prognostic significance is discussed controversially [86-92]. However, 
trastuzumab (Herceptin®), a recombinant monoclonal antibody against HER2/neu, which 
gained FDA approval for metastatic breast cancer, is currently under investigation in 
combination with conventional chemotherapy. In a multicenter phase II study with 44 
patients with HER-2/neu -positive advanced urothelial carcinoma, Hussain et al. [93] 
investigated the safety and efficacy of trastzumab, carboplatin, gemcitabine, and 
paclitaxel. Treatment was considered feasible with a response rate of 70% and a median 
survival of 14 months which was favorable as compared to results with 
gemcitabine/carboplatin. Ongoing studies will concentrate on the true contribution of 
trastuzumab and, in general, on finding the best way to detect HER2/neu in urothelial 
cancer as immunohistochemistry (IHC) and fluorescent in-situ hybridization (FISH) do 
not correlate to the same extent.  
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Dual EGFR/HER2 
Dual EGFR/HER2 inhibition is achieved with GW-572016/lapatinib (Tykerb®), which is 
also an orally active small molecule TKI. Being tested in a phase II study in pretreated 
bladder cancer patients, a median time of progression of 8.6 weeks was assessed, which 
was comparable to conventional second-line therapies [94].  
 
3.2. Ras signalling pathway 
Ras is a signal transduction protein which controls signaling pathways that are key 
regulators of several aspects of normal cell growth and malignant transformation [95]. As 
Ras mutations have been found in 30-40% of urothelial malignancies [96], blocking the 
activation of the Ras family oncogenes by farnesyl transferase inhibitors was also tested 
in bladder cancer treatment. Winquist et al. [97] evaluated the antitumor activity of SCH 
66336/lonafarnib in a phase II study with patients with previously treated transitional cell 
carcinoma (TCC). No single-agent activity was observed, and thus, an ongoing study 
concentrates on combined therapy with gemcitabine [78]. 
R115777/tipifarnib (Zarnestra®) is another farnesyl transferase inhibitor. As compared to 
lonafarnib, a phase II trial in patients with metastatic TCC of the urothelial tract, did not 
show single-agent activity [98]. At this, studies are still continued. Another approach 
combines trastuzumab with tipifarnib for bladder cancer treatment [78]. 
 
3.3. Phosphatidylinositol-3-kinase signalling pathway 
The mammalian target of rapamycin (mTOR) is a protein kinase of the 
phosphatidylinositol-3-kinase (PI3K)/Akt signalling pathway involved in cell growth, 
cell motility, cell survival, protein synthesis, and transcription [99]. As dysregulation of 
the mTOR pathway has been found in many human tumors, mTOR inhibitors are under 
investigation for cancer treatment. Currently, RAD001/everolimus (Certican®), which is 
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approved in Europe for drug-eluting coronary stents as an immunosuppressant to prevent 
restenosis, is under investigation in bladder cancer. In a phase II study the response rate 
and the effects of everolimus will be evaluated [78]. 
 
3.4. Cell cycle regulators 
Cyclin-dependent kinases (CDKs) are main regulators of cell cycle progression, and thus 
inhibition results in cell cycle arrest and even in apoptosis. Alvocidib (flavopiridol, HMR 
1275, L86-8275) is a semi-synthetic flavon which was the first cyclin-dependent kinase 
inhibitor in human clinical trials [100]. Evaluation in bladder cancer was performed by 
Chien et al. [101], who elucidated the effects of flavopiridol on normal urothelial cells, 
immortalized urothelial cell lines, and bladder cancer cell lines. They showed that 
flavopiridol is capable of inducing G2/M arrest, growth inhibition, and a modest level of 
apoptosis. Wirger et al. [102] additionally examined the toxicity and efficacy of 
flavopiridol in a rat bladder cancer model. Accordingly, this agent could be useful for 
bladder cancer therapy as 7 out of 12 rats were tumor-free and for the remaining tumors a 
tendency to lower stage and grade was demonstrated.  
 
3.5. Proteasome 
The ubiquitin-proteasome system is also involved in the regulation of cellular processes 
such as cell cycle and division, regulation of transcription factors, and cellular quality 
control by degradation of intracellular proteins. Thus, aberrations can play an important 
role in tumorigenesis and, consequently, the system has become a target for anticancer 
strategies [103]. 
PS-341/bortezomib (Velcade®), a specific and reversible inhibitor of the proteasome, is 
FDA approved for use in multiple myeloma. Kamat et al. [104] demonstrated for 253JB-
V bladder cancer cells, that bortezomib inhibits cell growth and augments the growth 
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inhibitory effects of gemcitabine. Besides accumulation of p53, p21 and suppression of 
cyclin-dependent kinase 2 activity, antiangiogenic effects by inhibiting MMP-9, IL-8, 
and VEGF were also reported. Recent clinical studies further investigate the efficacy of 
bortezomib therapy for patients with advanced or metastatic transitional cell cancer of the 
bladder, the renal pelvis, or the ureter [78]. 
 
3.6. DNA hypermethylation 
Aberrant DNA methylation has been shown to be a key survival mechanism in cancer. 
Inhibitors of DNA methylation, such as 5-azacytidine (5-Aza-CR), 5-aza-2-
deoxycytidine (5-Aza-CdR) and zebularine, act through reactivation of the expression of 
genes that have undergone epigenetic silencing [105]. For bladder cancer therapy, Bender 
et al. [106] evaluated the effects of 5-Aza-CdR on human cancer cell lines (bladder 
transitional carcinoma- and colon carcinoma-derived cell lines) and human fibroblast cell 
strains. Results revealed suppression of cell growth in the tumor cell lines which was 
associated with reactivation of growth-regulatory genes silenced by de nova methylation. 
Recently, Cheng et al. [107] showed an antitumor effect of zebularine on human bladder 
carcinoma cells transplanted in BALB/c nu/nu mice after oral administration supporting 
the feasibility in cancer treatment.  
 
3.7. Telomerase 
Human telomerase reverse transcriptase (hTERT) is an essential component in the 
telomerase complex controlling telomerase activity and is highly expressed in bladder 
cancer cells. Zou et al. [108] investigated anti-proliferative effects of small hairpin 
interfering RNA (shRNA)-targeted hTERT gene on bladder cancer cells and xenograft 
mice models. Results revealed down-regulation of hTERT expression, and decreasing 
telomerase activity leading to suppression of tumor growth. Gao et al. [109] also 
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observed enhanced apoptosis of cancer cells upon administration of hTERT antisense 
oligodeoxynucleotides followed by TNF-α. 
 
3.8. B-cell lymphoma 2 (bcl-2) 
Bcl-2 is an important anti-apoptotic factor, and overexpression has been reported in 
bladder cancer [110]. Bilim et al. [111] evaluated bcl-2 antisense phosphorothioate 
oligodeoxynucleotide (PODN)-mediated downregulation of bcl-2 expression on human 
bladder cancer cells. Treatment reduced the bcl-2 protein level and combined treatment 
with Adriamycin resulted in increased cytotoxicity. Another synergistic effect resulting 
in significant lower cell survival rates of bladder cancer cells was observable for 
combined treatment of bcl-2 antisense oligonucleotide and cisplatin [112]. Currently, a 
phase I/II trial aims to study the effectiveness of bcl-2 antisense oligonucleotide (G3139, 
oblimersen, Genasense®) in treating patients with solid tumors including bladder tumors 
[78]. 
 
3.9. Clusterin 
Clusterin (apolipoprotein J), a glycoprotein that is associated with a variety of functions 
such as regulation of apoptosis, has been reported to be overexpressed in several human 
cancers [113]. Miyake et al. [114] evaluated whether antisense (As) 
oligodeoxynucleotide (ODN) targeting the clusterin gene could enhance the cytotoxic 
effect of gemcitabine in human bladder cancer KoTCC-1 cells. The treatment resulted in 
significantly enhanced chemosensitivity of KoTCC-1 cells and administration in a 
murine intraperitoneal bladder tumour implantation model significantly decreased 
KoTCC-1 tumour volume. OGX-011/curtisen is a second generation antisense molecule 
which blocks production of clusterin and is currently under investigation in a phase I 
study in combination with docetaxel for therapy of patients suffering from metastatic or 
locally recurrent solid tumors (bladder, breast, kidney,…). 
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3.10. Survivin 
Survivin is an apoptosis inhibitor that is up-regulated in many malignancies including 
bladder cancer. In this context, Fuessel et al. and Ning et al. [115,116] evaluated the 
efficacy of anti-survivin As-ODNs for bladder cancer treatment. According to tests with 
diverse bladder cancer cell lines, the survivin- directed As-ODNs down-regulated the 
expression of the protein and inhibited proliferation.  
 
3.11. Tumor suppressor genes 
Alterations in p53 and pRb, the products of the chromosomes 17p13 TP53 and 13q14 
retinoblastoma (Rb) tumor suppressor genes, occur in almost 50% and 33% of bladder 
cancers, respectively, and are associated with advanced stages and higher grade of 
disease [117]. Thus, therapeutic strategies for restoration of the normal function are 
under investigation. 
 
p53 gene-based therapy 
An encouraging approach is the adenovirus-mediated transfer of wild-type human p53. 
The intratumoral injection of an adenoviral expression vector encoding wild-type p53 
(rAd/p53 or SCH 58500) in patients with invasive bladder cancer [118] revealed 
biological activity of the treatment without any dose-limited toxicity. In a phase I study 
Pagliaro et al. [119] investigated the feasibility, safety, and biological activity of another 
adenoviral vector containing the wild-type p53 gene, namely Ad5CMV-p53 (INGN201, 
Advexin®), in patients with locally advanced TCC of the bladder. Repeated installations 
were safely administered, but the efficiency of gene transfer turned out to be improvable 
as specific transgene expression was only observed in 2 out of 7 patients. Enhancement 
of the activity of Ad5CMV-p53 was observed in combination with cisplatin in a study 
with bladder cell lines [120] as well as in combination with As-ODN-targeting clusterin 
gene in a human bladder cancer model [121]. Another approach is the use of recombinant 
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vaccinia virus (rVV) as a vector for p53. In an orthotopic murine model, Fodor et al. 
[122] evaluated the efficacy of rVV-TK-53. The treatment resulted in decreased tumor 
incidence and in 33% survival, whereas the delivery using buffer or empty vector did not 
show any survival benefit. 
 
pRb gene-based therapy 
In preclinical studies with non-small cell lung carcinoma and bladder carcinoma cells, Xu 
et al. [123] evaluated the activity of RB94, a more potent tumour growth suppressor than 
the normal protein (Rb110), in a replication-deficient adenoviral vector 
(AdCMVpRB94). Gene therapy resulted in regression of the tumour of both Rb-negative 
and Rb-positive tumour cells and the pRB94, when overexpressed in tumour cells via 
replication-deficient adenovirus vectors, was evidently more potent in tumor suppression 
than the full-length RB protein. Generally, increasing emphasis for cancer gene therapy 
lies on the development and use of nonviral delivery methods which lack 
immunogenicity or biohazardous potential. In this context, Pirollo et al. [124] developed 
a systemically administrable, nanosized liposome delivery system with a tumor-targeting 
moiety, either the transferrin (Tf/Lip/RB94) or the anti-transferrin receptor single-chain 
antibody fragment (TfRScFv/Lip/RB94). Using an RB-negative human bladder 
carcinoma cell line, transfection with Tf/Lip/RB94 significantly sensitized cells for the 
chemotherapeutic agent. In mice bearing subcutaneous bladder tumors, the combination 
of systemically given Tf/Lip/RB94 or TfRScFv/Lip/RB94 plus gemcitabine resulted in 
significant tumor growth inhibition and/or regression as well as induction of apoptosis. A 
phase I study is aimed to evaluate this system in patients with metastatic RB-negative 
bladder cancer. 
 
3.12. Histone deacetylase 
Histone deacetylation is associated with transcriptional repression, including a decrease 
in the expression of tumor suppressor genes. Histone deacetylases (HDACs) are 
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overexpressed in various types of cancer, making them a potential target for cancer 
treatment. As HDACs also exert influence on the regulation of non-histone proteins such 
as heat shock protein 90 (Hsp90), p53, tubulin, Rb, and E2F1, HDAC-inhibitors seem to 
have a broad anti-cancer potential [125]. 
In terms of bladder cancer treatment, a fundamental study was performed by Canes et al. 
[126]. They investigated the effects of sodium butyrate (NaB) and trichostatin A (TSA), 
two histone deacetylase inhibitors, on bladder carcinoma cells and evaluated the 
inhibitory activity of TSA on cell growth. In a clinical trial, vorinostat (suberoylanilide 
hydroxamic acid (SAHA), NSC 701852, Zolinza), a small molecule inhibitor of HDAC 
and FDA approved for the treatment of cutaneous T cell lymphoma, was applied to 37 
patients with advanced cancer [127]. Results revealed safe administration of the agent at 
doses that inhibit HDAC activity in-vivo, and 4 (2 lymphoma and 2 bladder) patients had 
objective tumor regression with clinical improvement in tumor related symptoms. 
Currently, a phase I study of vorinostat in combination with doxetaxel in patients with 
advanced and relapsed malignancies including bladder cancers is under investigation 
[78]. 
Romidepsin (FK228, depsipeptide, FR901228), another HDAC inhibitor, significantly 
inhibited growth of TCC tumor in xenograft models [128]. An ongoing phase II trial 
deals with the activity of romidepsin in patients with advanced cancer of the urothelium 
including that of the bladder. 
 
3.13. Angiogenesis 
Angiogenesis, the process of new blood vessel formation from preexisting ones, is one of 
the fundamental steps in the development of metastatic bladder cancer, and therefore 
serves as a sound target for cancer therapy. Among the angiogenic factors, the most 
prominent one involved in bladder cancer is the vascular endothelial growth factor 
(VEGF). Binding to the receptor results in stimulating cell growth and proliferation, two 
key features for the development of new blood vessels, and increased vascular 
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permeability, which may also contribute to angiogenesis and tumour growth [129]. The 
function of VEGF in vessel formation is complemented by the plateled-derived growth 
factor (PDGF) and thus, PDGF signaling can indirectly regulate angiogenesis [130]. 
Another important factor is the basic fibroblast growth factor (bFGF), which provides 
endothelial cells and smooth muscle cells with signals for proliferation and survival 
[131]. In addition to the important role of angiogenic factors for diagnosis and prognosis 
of bladder cancer [132, 133], they as well as their receptors are also subject of therapeutic 
strategies.  
As blockade of the VEGF receptors has shown to decrease Ras signaling and DNA 
synthesis in bladder cancer cell lines [134], DC101, an anti-VEGFR monoclonal 
antibody, was applied to mice with metastatic human bladder carcinoma [135]. In this 
study, a significant anti-tumour efficacy was observed, especially when combined with 
paclitaxel. Another study of the same authors dealt with the effects of DC101 on receptor 
phosphorylation and apoptosis and revealed that agents targeting a single receptor may 
not be sufficient to completely inhibit tumor angiogenesis [136]. Bevacizumab 
(Avastin®) is another recombinant humanised monoclonal antibody interacting with 
VEGFR and is FDA approved for the first-line treatment of metastatic colorectal cancer 
in combination with an intravenous 5-fluorouracil-based regimen. Currently, a study 
combining cisplatin, gemcitabine and bevacizumab for therapy of metastatic transitional 
bladder cancer is under evaluation [78]. 
The VEGF receptor activity can also be inhibited by catalytic RNA molecules known as 
ribozymes, which can downregulate VEGF receptor function by specifically cleaving the 
VEGFR1-mRNA. A study in patients with advanced solid tumors including [137] 
bladder cancer and administration of RPI.4610 (Angiozyme), a stabilised ribozyme, in 
combination with carboplatin and paclitaxel revealed a complete response. The focus was 
set on the safety and the pharmacokinetics of RPI.4610 in this combined therapy and the 
results indicated safe administration without substantial pharmacokinetic interactions. 
Targeting VEGF instead of its receptor, VEGF Trap represents a potent angiogenesis 
inhibitor that consists of partial sequences of human VEGF receptor VEGFR1 and 
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VEGFR2 extracellular domains fused to the Fc portion of human immunoglobulin γ 
[130], which binds and inactivates VEGF with a high affinity. To date, a phase II trial is 
studying the side effects and the activity of VEGF Trap upon treatment of patients with 
recurrent, locally, advanced or metastatic bladder cancer [78]. 
BAY 43-9006/sorafenib (Nexavar®) is an orally adminstrable small molecule tyrosine 
kinase inhibitor, which is FDA approved for treatment of metastatic renal cell carcinoma. 
Inhibiting c-Raf, B-Raf, VEGFR2, VEGFR3 and PDGFR-B [138], it is currently under 
investigation for therapy of advanced and metastic bladder cancer [78]. 
SU11248/sunitinib (Sutent®) is another orally given, small molecule inhibitor of multiple 
tyrosine kinases, that targets PDGF, VEGFR, stem cell receptor factor (KIT), and fms-
like tyrosine kinase 3 (FLT-3) [139]. It is FDA approved for the treatment of renal cell 
carcinoma and Imatinib-resistant gastrointestinal stromal tumour. In preclinical bladder 
carcinoma models, Sonpavde et al. [140] assessed the efficacy of sunitinib or cisplatin 
and in combination. Anti-tumour activity was observed as a single agent and the activity 
of cisplatin was enhanced. Recently, Bradley et al. [141] designed a randomised phase II 
trial evaluating the role of sunitinib as maintenance therapy in advanced urothelial 
cancer. 
Endostatin protein is a naturally-occurring 20-kDa C-terminal fragment derived from 
collagen XVIII, which inhibits angiogenesis, and may interfere with the pro-angiogenic 
action of growth factors such as VEGF and bFGF [142]. Du et al. [143] investigated the 
efficacy of recombinant human endostatin to inhibit tumour growth in bladder cells. In 
contrast to tumour cells only proliferation of endothelial cells was inhibited, but in nude 
mice subcutaneous endostatin blocked angiogenesis and induced apoptosis in bladder 
cancer cells. Kikuchi et al. [144] evaluated lentivirus vector-mediated overexpression of 
endostatin and reported decreased vascularization and inhibition of bladder tumour 
growth. Thus, the application of endostatin seems to be a feasible concept, supported also 
by Schmidt et al. [145], who observed a distinct endostatin-binding pattern in bladder 
tumours as compared to benign tissue and malignant and benign kidney tissue.  
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TNP-470, an analogue of fumagillin and derived from Aspergillus fumigatus, is also a 
potent inhibitor of angiogenesis [146]. Various preclinical studies evaluated the efficacy 
for bladder cancer treatment of TNP-470 alone [147-149] or in combination with 
chemotherapeutics [150,151]. In general, they demonstrated the potential of TNP-470 to 
inhibit tumour growth and a synergistic antitumour effect with gemcitabine [151]. 
However, clinical data for bladder cancer are not available yet. 
NF-κB is a protein complex, which acts as a transcription factor regulating the expression 
of pro-angiogenic molecules. In a study with human TCC cell lines, Karashima et al. 
[152] showed that NF-κB mediates neo-angiogenesis and proliferation via interleukin-8 
which renders NF-κB a potential molecular target for bladder cancer therapy. 
Targeting bFGF, Inoue et al. [153] investigated adenovirus-mediated antisense bFGF 
gene therapy in mice with human bladder carcinoma. They successfully inhibited tumour 
growth by downregulating the expression of bFGF and MMP-9 which resulted in 
decreased tumour cell proliferation and enhanced apoptosis of tumour and endothelial 
cells. 
 
3.14. Glycocalyx  
In common with all eukaryotic cells, the surface of bladder cells is covered by a dense 
layer of complex carbohydrates collectively known as the “glycocalyx”. Biorecognitive 
proteins such as lectins are capable of detecting and binding to these carbohydrate 
moieties at the cell surface in a highly specific manner. Due to this carbohydrate-specific 
interaction and alteration of the glycosylation pattern of cells upon malignant 
transformation [154], lectin-mediated targeting might be an encouraging approach 
towards site specific antitumour therapy. At this, binding to and even uptake in colon 
cancer cells was demonstrated for prodrug formulations as well as nanoparticulate drug 
carriers grafted with certain lectins to render these delivery systems targeted [155,156]. 
Plattner et al. [157] evaluated the cytoadhesive and cytoinvasive properties of several 
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plant lectins for a human bladder cancer cell line and prescreened wheat germ agglutinin 
as potential target vehicle for functionalized drug delivery systems. 
 
 
4. Further Approaches 
The matrix metalloproteinase (MMP) family of extracellular proteinases is regarded as a 
critical factor assisting tumour cells during metastasis by degrading the extracellular 
matrix [158]. A key role in this process is featured by MMP-2 and MMP-9, which mainly 
fragment the basement membrane type IV collagen. Recently, a study with Magnolia 
officinalis was performed [159] to investigate the anticancer activity to urinary bladder 
cells. A suppressed expression of MMP-2 and MMP-9 was monitored and the treatment 
of mice with BBN-induced urinary bladder tumors revealed growth inhibition. However, 
preliminary results from clinical trials aimed at therapy of various cancers have been 
disappointing [160], and thus the numerous functions of MMPs must be further 
investigated in order to find out effective targeting strategies. 
 
Another target of future interest might be the Hsp90, which has been found to be 
overexpressed in several tumors including those of the bladder and is associated with 
progression of pathogenic cellular transformation [161,162]. Several Hsp90 inhibitors 
have entered clinical evaluation, which showed successful targeting, but advances are 
required to increase clinical outcomes in a wider range of cancers [163]. 
 
An interesting therapeutic approach is also the use of magnetic targeted carriers, which 
are microparticles formed from metallic iron and activated carbon. The iron provides 
magnetic manipulation and the carbon component allows absorption of doxorubicin 
(MTC-DOX). After intravesical instillation, targeting is achieved with the use of an 
externally placed magnet. Leakakos et al. [164] demonstrated for normal swine bladders 
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that MTC delivery allowed a greater exposure and site specific deposition of the drug in 
comparison to doxorubicin alone, but the proof of principle for the treatment of bladder 
cancer is still an open task.  
 
Moreover, cell-penetrating peptides (CPP) or protein transduction domains (PDT) have 
become widely used vehicles for the cellular import of molecules, as they have been 
shown to be internalized in most cell types and can transport numerous types of drugs 
into cells including small-molecule pharmaceuticals, therapeutic proteins, and antisense 
oligonucleotides [165]. Schwarze et al. [166] synthesised a 15-oligomer peptide 
containing an NH2-terminal 11-amino PDT from the human immunodeficiency virus 
TAT protein. The administration resulted in delivery of the biologically active fusion 
protein to all tissues in mice, including the brain. This lack of specificity might be 
problematic in case of systemic use, nevertheless, for intravesical therapy it could be of 
further interest. 
 
Regarding bladder cancer treatment, also improved immunotherapeutic strategies have to 
be mentioned. The purpose of immunotherapy is to stimulate the immune system against 
tumour cells via either passive or active immunisation. A promising approach is direct 
induction of cytokines such as IL-2, IL-12, and interferons into cancer cells. The 
feasibility of an intravesical liposome-mediated IL-2 gene transfection was evaluated 
from Horiguchi et al. [167] in an orthotopic mouse bladder cancer model. Results 
revealed inhibited tumor growth and prolonged survival, which was enhanced by 
addition of subsequent B-7.1 (a surface immune molecule) gene-modified tumor vaccines 
[168]. Administration of IL-12 was investigated by O´Donnell et al. [169] in mice with 
transitional cell carcinoma of the bladder. Treatment resulted in prolonged survival and 
cured subjects (75%) at the highest IL-12 dose, and anti-tumor effects were observed 
after both systemic and intravesical administration. A preclinical study was conducted by 
Lee et al. [170] to examine the efficacy of murine IL-12 DNA vaccine and recombinant 
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BCG DNA vaccines in a murine bladder tumour model. The combination of both 
vaccines resulted in a high serum interferon-γ level, which promotes Th1 type of immune 
responses, and was associated with a significantly higher survival rate than that of mice 
treated with either vaccine alone or that of control mice. High expression of IL-12 can 
also be induced with AdCD40L gene therapy [171]. CD40L is a type II transmembrane 
protein belonging to the tumour necrosis factor superfamiliy, and the gene was 
transferred by adenoviral vectors to mice with orthotopic bladder cancers [171]. A 
systemic tumour-specific immune response was stimulated and 60% of mice with pre-
established tumours were cured. Efficient gene delivery and expression of interferon α-2b 
protein has been achieved using a recombinant adenovirus gene delivery system (rAd-
IFN) together with the small molecule excipient syn3 [172]. Results revealed increasing 
exposure of IFN and significant tumour reduction in a mouse model with human bladder 
cancer. 
 
Finally, the role of radiochemotherapy (RCT) is under discussion in bladder cancer 
treatment. As radiotherapy (RT) alone has not shown to be superior to other conservative 
treatments [173], several studies have investigated the role of combined RT with 
chemotherapy to improve the outcome for patients [174-177] and suggested higher 
response rates and improved survival. Current approaches also concentrate on improved 
strategies in combination with hyperthermia [178] or inhibition of oncogene products 
such as HER2/neu in combination with RCT using paclitaxel and trastuzumab [179]. 
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5. Expert opinion 
Given the high tendency to recur together with the ever-present possibility to progress, 
successful treatment of bladder cancer is still a challenge for urologists and oncologists. 
Until now the primary goal has been to eradicate the local and any potential 
micrometastatic disease and at the same time to maintain the highest quality of life 
without compromising survival. Apart from surgical approaches, current treatment 
modalities comprise primarily non-specific immuno- or chemotherapy, but the response 
is often insufficient. Due to the physiology of the urothelium efficacy of treatment is 
governed by two crucial factors: the permeability of the bladder wall and the residence 
time of the API to maintain an adequate concentration gradient for passive diffusion. 
Improved permeability could be achieved via chemical and physical approaches also with 
good clinical results. However, all of these methodologies rely on non-specific 
permeation enhancement which might provoke some adverse side effects.  
As to the residence time, conventional formulations typically stay in the bladder for only 
a short time of about 2 hours. Since a sufficiently high concentration gradient represents 
a crucial parameter for passive diffusion and thus efficacious treatment, a constantly 
elevated API-level in the bladder for a prolonged period would be desirable. Among the 
vehicles used for intravesical therapy colloidal carriers might be of particular importance 
especially in future. If these particles are refined with additional bioadhesive properties 
appropriate sustained release characteristics together with an often essential improve in 
stability of the API might be feasible. 
 
However, all these modalities lack any clear discrimination between healthy and diseased 
tissue. Since the time of Paul Ehrlich pharmaceutical technologists all over the world 
dream of the “magic bullet”, a drug delivery system that has the ability to specifically 
target diseased cells. Especially in the field of chemotherapy with its numerous and 
severe side effects, site specific delivery and action of the API without compromising 
non-target cells are profound prerequisites for a more convenient regimen. Molecular 
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targeting might be a step forward in this area. Based on the increased understanding of 
the biological mechanisms underlying bladder carcinogenesis and tumour progression, 
various potential molecular targets have been identified and evaluated in preclinical 
studies, such as the signalling pathways playing a crucial role in the regulation of cell 
growth. Among others, the receptors of epithelial growth factor, which were found to be 
overexpressed in bladder cancer cells, have been addressed as attractive targets. Though 
preclinical data suggested positive aspects, the clinical benefits remain limited. This 
might also be due to the fact that EGFR expression is varying and there is often no clear 
correlation between overexpression of these receptors and tumour prognosis in bladder 
cancer. Possibly, response rates could be improved by an optimised patient selection 
using predictive molecular markers. According to the literature, application of specific 
inhibitors affecting the signalling pathway in a single-agent therapy seems to be 
generally less effective as compared to combination regimens using either 
chemotherapeutics or biologic agents that target a different part of the tumourigenetic 
cascade. At this, further therapeutic improvements might be achieved using sophisticated 
drug delivery systems instead of a simple parallel application. These systems might 
consist of nanoparticles that contain the cytotoxic agents in their core and are decorated 
with a corona of biologicals which guarantee the specific targeting.  
Another approach towards targeted therapy relies on strategies acting at the genetic level. 
Various preclinical in-vitro and in-vivo studies suggested the principal feasibility of gene 
therapy for bladder cancer treatment. Currently, several phase I/II trials using either As-
ODNs for suppression of oncogenic genes or tumour supressor genes for restoration of 
adequate cell cycle regulation are performed with promising results. Due to the rather 
easy access of the diseased tissue via intravesical instillation adequate delivery of the 
therapeutic genes to the cells of interest seems to be a manageable task making gene 
therapy a practicable option for treatment of bladder cancer. However, refinement of 
vector systems remains a challenge for future research in order to increase the 
transfection efficacy and its specificity. Despite encouraging results, a final decision 
about the potential of gene therapy in bladder cancer cannot be given yet.  
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With special emphasis on advanced bladder cancer also anti-angiogenic approaches 
might hold promise. Prominent targets in this area include either proangiogenic factors 
such as VEGF and bFGF or the corresponding receptors. Some of the strategies directed 
against angiogenesis of bladder tumours revealed their potential already in clinical trials 
and might become even more important in future.  
An interesting alternative strategy towards improved selectivity of chemotherapy in 
bladder cancer might represent the application of lectins. Offering a clear discrimination 
between healthy and diseased cells, the advantage of the glycotargeting approach relies 
not only on the specific enrichment of lectin at the surface of malignant cells but also on 
the fact that some lectins are able to actively transport conjugated drugs across the 
cellular membrane. That way, the chemotherapeutic agent might be accumulated directly 
in the cytosol of the targeted cancer cells, if the API and the targeter are linked in a 
proper way either as a prodrug formulation or a carrier system.  
 
All in all, pure combination chemotherapy in bladder cancer treatment has reached a 
plateau. However, novel biological therapies appear as a silver lining on the horizon of 
bladder cancer therapy that will gain increasing interest in future due to their targeting 
facilities. The challenge to be faced in this area by investigators all over the world is how 
to intelligently combine controlled and targeted delivery approaches in order to gain 
maximal treatment efficacy and thus therapeutic benefit for the patient with minimal 
physiological stress. Given the current efforts this might already be achievable within our 
lifetime. 
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ABSTRACT 
In the present study plant lectins with distinct sugar specificities were applied to two 
blood-brain barrier (BBB) mimicking cell lines, namely human ECV304 and porcine 
brain microvascular endothelial cells (PBMEC/C1-2) in order to elucidate their 
glycosylation pattern and to evaluate the lectin-cell interaction for lectin-mediated 
targeting. The bioadhesive properties of fluorescein-labeled lectins were investigated 
with monolayers as well as single cells using fluorimetry and flow cytometry, followed 
by confirmation of the specificity of binding. For PBMEC/C1-2 layers highest binding 
capacity was found for wheat germ agglutinin (WGA), followed by Dolichus biflorus 
agglutinin (DBA) whereas single cell experiments revealed a predominance of DBA 
only. Analyzing ECV304 monolayers and single cells, WGA yielded the strongest 
interaction without any changes during cultivation. The binding capacities of the other 
lectins increased significantly during differentiation. As similar results to primary cells 
and brain sections were observed, both cell lines seem to be suitable as models for lectin-
interaction studies. Thus, an additional focus was set on the mechanisms involved in 
uptake and intracellular fate of selected lectins. Cytoinvasion studies were performed 
with WGA for human ECV304 cells and WGA as well as DBA for PBMEC/C1-2 cells. 
For both lectins, the association rate to the cells was dependent on temperature which 
indicated cellular uptake.  
 
 
Keywords: blood-brain barrier; ECV304; PBMEC/C1-2; lectins; drug targeting 
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INTRODUCTION 
Unlike peripheral endothelium, brain microvascular endothelial cells (BMEC) are 
characterized by minimal pinocytotic activity, the absence of fenestrations and the 
presence of tight intercellular junctions [1]. They are the main components of the blood-
brain barrier (BBB) which maintains the homeostasis of the brain microenvironment and 
strongly restricts the transport of many drugs from blood to brain.  
The surface of the BMECs is covered by a dense layer of complex carbohydrates 
collectively known as the “glycocalyx” which is thought to contribute to the barrier 
function [2-4]. Biorecognitive proteins such as lectins are capable of detecting and 
binding to these carbohydrate moieties at the cell surface by a highly specific interaction. 
Consequently, lectins may serve as a tool for analysis of the carbohydrate composition of 
the glycocalyx. Additionally, several studies have outlined the perspectives of lectin-
mediated drug delivery [5-7] including glycotargeting of the BBB [8,9].  
As investigation of the blood-brain barrier and its function in vivo is a challenging task, 
in vitro models mimicking blood-brain barrier characteristics are useful tools for 
preliminary studies. Primary brain endothelial cells seem to retain more properties of the 
original tissue, but cultivation is time-consuming and cells have a limited lifespan. Thus, 
particularly for drug delivery studies cell culture models are preferred as the phenotypic 
characteristics are stable over a long period including good reproducibility of data. 
Moreover, cultures of cell lines can easily be cultivated and expanded at will which 
reduces cost and labor [10]. For that reason, two of the most promising BBB mimicking 
cell lines, namely human ECV304 and porcine PBMEC/C1-2, were chosen for 
systematic characterization of the lectin binding pattern at the monolayer and single cell 
level. The ECV304 cell line was introduced by Takahashi et al. [11] and recommended in 
a previous study to be suitable for BBB drug transport studies [12]. The cell line 
PBMEC/C1-2 was established by Teifel and Friedl [13] and used as an in vitro model of 
the BBB in several studies [12,14,15] Both cell lines were cultured in astrocyte 
conditioned medium (ACM) in order to induce typical BBB properties [12, 16, 17].  
The aim of this study was to assess the binding characteristics and binding specificities of 
several plant lectins with distinct carbohydrate combining sites on these cell lines. To 
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cover a broad range of sugar structures at the cell surface, lectins were chosen as follows: 
wheat germ agglutinin (WGA), Solanum tuberosum lectin (STL), Lens culinaris 
agglutinin (LCA), Ulex europaeus isoagglutinin I (UEA-I), Dolichus biflorus agglutinin 
(DBA) and peanut agglutinin (PNA). Ongoing from these results, an estimation of the 
glycosylation pattern of cell lines ECV304 and PBMEC/C1-2 and their feasibility as 
BBB models for elucidation of lectin-mediated drug delivery should be possible. An 
additional focus was set on the mechanisms involved in uptake and intracellular fate of 
selected lectins as beneficial for targeted drug delivery. 
 
MATERIALS AND METHODS 
Materials 
Isocove’s modified Dulbecco’s medium (IMDM), Ham’s F12, Newborn calf serum 
(NCS), L-Glutamine, Penicillin/Streptomycin and Trypsin/EDTA were bought from 
Invitrogen Corporation (GibcoTM, CA, USA). Transferrin, Amphotericin B and Gelatine 
were purchased from Sigma (MO, USA). Heparin was obtained from Fluka (Buchs, 
Switzerland). Cell culture flasks and 96-well plates were bought from Greiner Bio-one 
(Kremsmünster, Austria). 
Fluorescein-labeled WGA (molar ratio fluorescein/protein (F/P) = 2.9), STL (F/P = 3.1), 
LCA (F/P = 3.8), UEA-I (F/P = 2.7), DBA (F/P = 2.2) and PNA (F/P=5.2) were 
purchased from Vector laboratories (Burlingame, USA) and contained >98% active 
conjugate and no free fluorescein.  
 
Cell culture 
Cell line C6 derived from a rat glioma [18] was used in order to produce ACM. They 
were obtained from the German Cancer Research Center Heidelberg (DKFZ, Heidelberg, 
Germany) and cultured in C6 medium. The C6 medium is a 1:1 mixture of Ham’s F12 
and IMDM supplemented with 7.5 % (v/v) new born calf serum (NCS), 7 mM L-
Glutamine, 5 µg/ml Transferrin, 0.5 U/ml Heparin, 100 U/ml Penicillin, 100 µg/ml 
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Streptomycin and 0.25 µg/ml Amphotericin B. In order to obtain ACM the supernatant of 
a C6 culture was collected every other day.  
PBMEC/C1-2 cells were a kind gift from Teifel and Friedl [13] and cultured in PBMEC 
medium (50 % C6 medium, 50 % ACM). 
The ECV304 cell line was purchased from the European Collection of Animal Cell 
Cultures (ECACC, Wiltshire, UK) and also maintained in PBMEC medium. For single 
cell studies cells were seeded on gelatine-coated culture flasks and grown to confluence. 
Cells were harvested by trypsination, centrifuged (1000xg, 4°C, 10 min) and resuspended 
in PBMEC medium at a concentration of 6x106 cells/ml. For monolayer studies cells 
were seeded on gelatine-coated 96-well plates at a concentration of 80 000 cells/cm2 and 
grown to confluence. Lectin interaction studies were carried out on day 4 with both cell 
lines and additionally on day 14 with ECV304 cells only. All cells were cultured at 37°C, 
5 % CO2 and 96 % humidity. 
 
Cytoadhesion studies 
Lectin binding was investigated using both monolayers and single cells. Monolayers 
cultivated in 96-well plates were washed twice with 150 µl PBS per well prior to 
incubation with 50 µl of the particular lectin solution (3.125-100 pmol/well, serial 
dilution) for 20 min at 4°C. At this temperature the metabolism of the cell is down 
regulated, and energy dependent transport processes are repressed. Consequently, the 
amount of cell-associated lectin refers basically to cytoadhesion. 
Excess of lectin was removed by washing the monolayers twice with 150 µl PBS. Then, 
50 µl PBS were added and the mean fluorescence intensity (MFI) of each well was 
determined using a fluorescence microplate reader (Infinite M200, Tecan, 
Grödig/Salzburg, Austria). Blanks were prepared accordingly but using PBS instead of 
the lectin solution and the values obtained were subtracted from all data quoted. 
Experiments were carried out in quadruplicate. 
Single cells were processed immediately after trypsination. 50 µl cell suspension (3.0 x 
105 cells) were incubated with 50 µl of a dilution series of the respective lectin in PBS 
(3.125-100 pmol/assay) for 5 min at 4°C. Then, 100 µl PBS were added and cells were 
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spun down (1000 rpm, 5 min, 4°C). The supernatant was discarded and this washing step 
was repeated twice to remove any unbound lectin. To obtain a suitable single cell 
suspension, the cells were diluted with 1 ml particle free PBS followed by flow 
cytometric analysis. In order to estimate the autofluorescence of the cells, control 
samples with unlabeled cells were included in all experiments and the acquired values 
were subtracted from all data quoted. Experiments were carried out in triplicate. 
 
Specificity of the lectin-cell interaction 
Specificity of lectin binding was verified by competitive inhibition using the 
corresponding carbohydrates (Table 1). 
Confluent monolayers were washed twice with 150 µl PBS prior to incubation with 100 
µl of the complementary carbohydrate in PBS and 50 µl of the corresponding lectin in 
PBS (25 pmol/well) for 20 min at 4°C. After a washing step with PBS, cell layers were 
analysed by fluorimetry after adding 50 µl PBS. For each lectin the amount of inhibitory 
sugars added is displayed in Table 1.  
For single cell experiments, 50 µl cell suspension (3.0 x 105 cells), 100 µl of a dilution 
series of the lectin-specific carbohydrate and 50 µl of a solution containing 25 pmol 
lectin were processed as described above. 
 
Cytoinvasion studies 
In order to investigate potential internalisation of lectins, uptake of WGA by ECV304 
cells was studied in detail using single cells. In case of PBMEC/C1-2 cells uptake of 
WGA and additionally DBA was elucidated. 
At this, 50 µl cell suspension (3.0 x 105 cells) were incubated with 50 µl of the respective 
lectin solution (25 pmol WGA or 25 pmol DBA/assay) for 5 min at 4°C (pulse 
incubation). Unbound lectin was removed as described above, and cells were further 
incubated for 0-240 min at 37°C or 4°C. As described previously, at 4°C interaction 
between the lectin and the cell is limited to binding to the cell surface, whereas at 37°C 
cells are metabolically active allowing energy consuming transport processes. At the end 
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of the chase-incubation, MFI values were acquired by flow cytometry. Then, 40 µl 
monensin solution (2.4 mM in EtOH) were added to the cells followed by a further 
incubation for 3 min at room temperature. Finally, the MFI was assessed again. 
 
Flow Cytometry 
Flow cytometric measurements were carried out on an Epics XL-MCL analytical flow 
cytometer (Coulter, FL, USA). Data were acquired using a forward versus side scatter 
gate to detect the single cell population and exclude cell aggregates and debris. 
Fluorescence emission was detected at 525 nm (10 nm bandwidth) after excitation at 488 
nm. 3000 cells per sample were acquired and for further calculations the mean channel 
number of the logarithmic fluorescence intensities of individual peaks (MFI) was used. 
Amplification of the fluorescence signals was adjusted to put the autofluorescence signal 
of unlabelled cells in the first decade of the four-decade log range. Data analysis was 
performed using Coulter System II software 3.0. 
 
Fluorescence microscopy 
To confirm binding and uptake of fluorescein-labeled lectins, fluorescence microscopy 
was used to visualize these processes: ECV304 and PBMEC/C1-2 cells were stained by 
incubating 50 µl cell suspension (3.0 x 105 cells) with 50 µl of the respective lectin 
solution (25 pmol WGA/assay for ECV304; 25 pmol WGA/assay and 25 pmol 
DBA/assay for PBMEC/C1-2) for 5 min at 4°C. Then, unbound lectin was removed as 
described above and cells were further incubated for 240 min at 37°C. Then, cells were 
washed again and immediately mounted for microscopy without fixation. Control 
samples were incubated at 4°C. Images of labeled cells were obtained using a Nikon 
Eclipse 50i microscope equipped with an EXFO X-Cite 120 fluorescence illumination 
system. Excitation and emission filter blocks were at 465-495/515-55 for green 
fluorescence. Fluorescence pictures were acquired at 40x magnification using Lucia G 
v5.0 software for image evaluation.  
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Statistical analysis 
Statistical analyses were carried out comparing two means from independent (unpaired) 
samples (t-test) using the Microsoft Excel® integrated analysis tool. P values of <0.05 
were considered as significant.  
 
RESULTS 
Lectin-binding capacity of PBMEC/C1-2 cells 
Six plant lectins with distinct carbohydrate specificities were selected to estimate the 
binding capacity of PBMEC/C1-2 cells and thus to characterize the glycosylation pattern 
of the cell surface. At this, monolayers were grown to confluence and incubated with the 
fluorescein-labeled lectins. For comparison of the data obtained, MFI values of each 
lectin were related to an apparent conjugation number of 1 mol fluorescein per mol 
lectin. Generally, the amount of cell-bound lectin increases with the amount of lectin 
added. As depicted in Figure 1, the lectin-binding to monolayers follows the order: 
WGA>DBA>LCA=STL>PNA>UEA-I. In case of WGA and DBA, a pronounced 
binding was observed in presence of 6.25 pmol lectin and above with fluorescence 
intensities in the range from 70.0±3.3 to 1476.8±58.8 MFI (WGA) or from 98.3±15.0 to 
1097.7±72.6 MFI (DBA).  
Additionally, flow cytometric analyses were performed to estimate the binding to single 
cells. The histograms revealed homogenous staining of all cells without appearance of 
unstained subpopulations. Interestingly, the resulting saturation curves (data not shown) 
were different from those of the monolayer assays. The strongest lectin - interaction with 
the cell surface was observed with DBA (MFI values up to 20.6±1.4) followed by 
STL>LCA>WGA>PNA>UEA-I. This ranking of lectin-binding capacity remained stable 
over the applied concentration range between 3.1 and 100 pmol lectin/analysis and is 
shown in Figure 2 at a concentration of 25 pmol. In this figure, the MFI of the lectin with 
the highest binding capacity was set to 100% and the binding capacities of the other 
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lectins were related to this. Thus, a comparison of the lectin binding pattern of 
monolayers and single cells should be possible, which is also depicted in Figure 2.  
 
Lectin-binding capacity of ECV304 cells 
For ECV304 monolayers, which were cultivated for 4 days, highest binding capacity was 
assessed for WGA with fluorescence intensities between 63.0±7.7 and 1108.1±65.1 MFI 
(Fig. 3). In presence of 25 pmol WGA/well the fluorescence intensity was 2.9, 5.9, 11.6 
or 14.7-fold higher as compared to STL, LCA, UEA-I or PNA, respectively.  
In order to follow alterations in the glycosylation pattern during cultivation, saturation 
experiments were additionally performed with ECV304 monolayers grown for 14 days. 
Interestingly, after prolonged cultivation WGA binding was only slightly increased with 
fluorescence values between 100.5±5.7 and 1374.0±43.6 MFI (data not shown), whereas 
the binding capacity of the other lectins increased notedly. As exemplified at a 
concentration of 25 pmol, WGA showed no significant increase between 4 days and 14 
days cultivation (p>0.05), whereas the binding of all other lectins significantly increased 
(p<0.01 for STL, LCA, PNA; p<0.05 for UEA-I; Fig. 4). Thus, after 14 days of 
cultivation, the cell-bound fluorescence intensity of WGA was only 2.2, 2.8, 7.0 and 8.4 
fold higher as compared to STL, LCA, UEA-I and PNA.  
Analyses of single cells led to saturation curves following the same order as for 
monolayers (data not shown). WGA yielded fluorescence intensities between 0.4±0.1 and 
34.5±2.8 MFI followed by STL (0.0±0.0 to 11.8±1.9 MFI) and LCA (0.1±0.0 to 
2.9±0.3). Figure 4 summarizes the lectin-binding capacity at a concentration of 25 
pmol/analysis for monolayers and single ECV304 cells. Interestingly, at this 
concentration LCA possessed a higher binding capacity in comparison to STL (1.4±0.1 
MFI as opposed to 0.6±0.2 MFI).  
DBA generally yielded very low MFI values scarcely above the autofluorescence of the 
cells for both, monolayers and single cells.  
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Specificity of the lectin-cell interaction 
The specificity of the lectin-binding was investigated by competitive inhibition using a 
dilution series of the corresponding carbohydrate and a constant amount of lectin. 
Depending on the amount of sugar added, the carbohydrate combining site of the lectin is 
blocked and inhibited from binding to the cell surface. For confluent PBMEC/C1-2 and 
ECV304 layers, the applied sugar concentrations and the resulting inhibition values are 
listed in Table II. These data show that the amount of cell-bound lectin decreases in 
presence of increasing amounts of the corresponding carbohydrate. Regarding the degree 
of inhibition, highly specific binding of the respective lectin to cellular structures was 
determined for ECV304 cells with inhibition values of more than 80% for each 
individual lectin. In case of PBMEC/C1-2 cells, WGA (93%) and DBA (86%) revealed a 
highly specific interaction. As the inhibition curves (not shown) are flattening at these 
percentages, the amount of unspecific binding might be estimated. In case of ECV304 
cells, up to 6% of WGA were found to be unspecifically bound, whereas for PBMEC/C1-
2 cells the unspecifically bound fraction was at the most about 7% in case of WGA and 
14% in case of DBA. 
However, it has to be considered that there are major differences in the binding behaviour 
between lectins and their corresponding mono- and oligosaccharide as well as derivatives 
due to varying affinities. Thus, the calculated specificities are only valid for the 
respective sugar used and the quoted specificity is assumed to be an asymptotic 
approximation commonly used in lectin studies to verify that binding to the cells is 
specific as it can be blocked by increasing amounts of sugar added. 
For comparison of the inhibition data between the cell lines, IC50 values were calculated 
from inhibition curves of each lectin and displayed in Table 2. The IC50 is defined as the 
amount of inhibitory sugar which half-inhibits the lectin-cell interaction.  
For WGA and PNA no significant differences were observed between the cell lines, 
whereas the other lectins revealed a stronger affinity to PBMEC/C1-2 than to ECV304 
cells.  
Specificity of binding was also ascertained for single cells. For both cell lines, a high 
degree of specific binding was detected for all lectins (data not shown). Interestingly, the 
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estimated specificity of UEA-I with PBMEC/C1-2 single cells was higher than that with 
monolayers yielding an inhibition curve that leveled off at 95% after addition of 0.5 µmol 
L-fucose. However, this might also be due to a lower affinity of the interaction between 
UEA-I and the single cells. The other lectins showed similar inhibition values as 
compared to the monolayer results. As to ECV304 cells, data similar to monolayer assays 
were obtained for all lectins with highest inhibition values for STL (92% after addition of 
0.125 µmol chitotriose).  
 
Uptake of WGA and DBA into PBMEC/C1-2 cells 
During pulse incubation at 4°C, WGA was allowed to bind to the cell membrane of 
PBMEC/C1-2 cells followed by removal of unbound lectin to guarantee identical starting 
conditions. Then, chase incubation at 37°C was started and resulted in a time-dependent 
decrease of MFI finally yielding a difference of 3.9±0.3 MFI after 240 min as compared 
to samples incubated at 4°C for the same time (7.3±0.4 MFI). Upon addition of monensin 
the reduced MFI could be restored approaching that of the control samples measured 
immediately after pulse incubation (0 min, 7.0±0.1 MFI). Control samples prepared at 
4°C revealed no considerable differences between MFI values prior to and after 
monensin addition throughout the incubation time (data not shown). 
For DBA, the lectin-cell interaction after pulse incubation at 4°C resulted in MFI values 
of 56.3±6.1. At the end of the chase incubation after 240 min a difference of 33.1±3.6 
MFI was detected between samples incubated at 4°C (60.6±4.7 MFI) and 37°C (27.5±5.7 
MFI), respectively. In contrast to WGA, the addition of monensin did not result in a full 
recovery of the reduced fluorescence intensities. It only increased from 27.5±5.7 (240 
min, 37°C, without monensin) to 37.1±7.2 (240 min, 37°C, with monensin). Control 
samples prepared at 4°C reacted as described above (data not shown).  
 
Uptake of WGA into ECV304 cells 
In case of ECV304 cells, membrane-association of WGA after pulse incubation at 4°C 
amounted to 54.0±5.9 MFI. During chase incubation, a difference of 25.8±1.2 MFI was 
assessed after 240 min between samples incubated at 4°C (53.8±3.7 MFI) and 37°C 
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(27.9±1.1 MFI). Again, reduced MFI values could be restored upon addition of monensin 
and control samples prepared at 4°C revealed no differences of MFI values prior to and 
after monensin addition (Fig. 5). 
 
Fluorescence microscopy 
For both cell lines, the images acquired after incubation at 4°C confirmed that the lectins 
bind exclusively to the surface of the cells as indicated by a fluorescent ring encircling 
the cell, when the focus was set to the middle of the cells. Incubation at 37°C gave 
decisive hints towards intracellular enrichment for WGA in case of ECV304 cells and for 
WGA as well as DBA in case of PBMEC/C1-2 cells, as the fluorescence was 
predominantly located within the cell (Fig. 6).  
 
DISCUSSION 
In this study different plant lectins with distinct sugar specificities were applied to the 
human cell line ECV304 and the porcine cell line PBMEC/C1-2 in order to elucidate the 
carbohydrate composition of the glycocalyx and to evaluate the scale of lectin-cell 
interactions for lectin-mediated targeting. Since precise determination of the total amount 
of non-specific binding by competitive inhibition assays is sometimes not feasible and 
both, specific and unspecific binding will contribute to the lectin interaction in vivo when 
applied for drug delivery purposes, total binding of the lectin was assumed to be most 
appropriate. Ongoing from the lectin-binding pattern of PBMEC/C1-2 monolayers the 
detectable carbohydrate composition can be characterized as follows: N-acetyl-D-
glucosamine and N-acetyl-neuraminic acid as corresponding carbohydrates of WGA 
seem to be prevailing and accessible, followed by N-acetyl-D-galactosamine detectable 
via DBA. N-acetyl-D-glucosamine and α-mannose, complementary sugar moieties of 
STL and LCA, are likewise present, followed by galactosamine (PNA) and L-fucose 
(UEA-I)-containing structures, which were found to be less abundant. These findings are 
mostly in accordance to Fischer and Kissel [9] who stained primary capillary endothelial 
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cells from porcine brain with lectins and detected a strong affinity for WGA, followed by 
DBA. In this study, no affinity was found for PNA, whereas Plendl et al. showed labeling 
of endothelial cells isolated from the brain of fetal pigs [19]. Besides WGA, UEA-I was 
proposed for the characterization of porcine capillary endothelium [9]. Nevertheless, the 
marginal occurrence of UEA-I binding sites on PBMEC/C1-2 cells was quite predictable 
as Teifel and Friedl did not detect UEA-I binding of this cell line using a different 
fixation method and lower concentrations [13]. Previous studies reported alterations in 
the sugar composition during BBB development [2,4] and a different lectin-binding 
pattern after changes in the barrier function [20,21]. For PBMEC/C1-2 cells these 
possible changes in the glyocalyx composition due to the influence of age and 
differentiation could not be assessed as the cells start to detach within 4 days after 
reaching confluence [12]. Therefore, lectin binding studies were only carried out on day 
4 after seeding.  
Experiments with single cells resulted in an apparent predominance of N-acetyl-D-
galactosamine structures (DBA). Interestingly, N-acetyl-D-glucosamine and N-acetyl-
neuraminic acid residues corresponding to WGA-binding were found to be less abundant 
whereas the lectin-binding capacities of the other lectins remained similar. These 
differences might be due to a loss of cellular polarity or the use of trypsin prior to the 
single cell experiments. 
Comparing the results of monolayer and single cell studies, cultivation of PBMEC/C1-2 
monolayers appears more appropriate for lectin-interaction studies as the lectin binding 
pattern on monolayers better correspond to primary endothelial cells and cortical brain 
sections. Ongoing from this good correlation, this cell line seems to be suitable as an in 
vitro model of the BBB for lectin-mediated drug delivery studies. 
Lectin-binding studies using ECV304 monolayers cultivated for 4 days resulted in a 
glycosylation pattern as follows: N-acetyl-D-glucosamine and N-acetyl-neuraminic acid 
moieties as detected by WGA are highly accessible and therefore probably most 
abundant. According to their detection the other accessible sugar residues follow the 
order: N-acetyl-D-glucosamine (STL)>α-mannose (LCA)>L-fucose (UEA-
I)>galactosamine (PNA) and N-acetyl-D-galactosamine (DBA). Since ECV304 cells 
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differentiate over two weeks [12,17], ECV304 monolayers were also cultivated for 14 
days. Results revealed significant changes of the amount of the respective lectin-binding 
sites except for N-acetyl-D-glucosamine and N-acetyl-neuraminic acid residues reflected 
by WGA-interaction. Increase of UEA-I binding during cultivation, which was 
previously found and described as an endothelial cell feature of ECV304 cells [22], 
underlines once more the endothelial character of this cell line and its utility as an BBB 
in vitro model. No changes were observed with respect to the ranking of the lectin-
binding capacities. As above, highest binding rates were detected for WGA.  
Single cell assays with ECV304 cells revealed a lectin-binding ranking similar to that of 
monolayer studies. However, there is only a limited number of accessible binding sites 
for UEA-I and PNA in comparison to monolayers, so that cultivation of ECV304 
monolayers seems more appropriate.  
Comparing the monolayer studies after 4 days in culture, both cell lines yielded the 
highest binding capacity for WGA together with a high binding specificity. The almost 
complete absence of DBA binding sites on ECV304 cells as opposed to PBMEC/C1-2 
cells may be due to the human origin of ECV304 cells as N-acetyl-galactosamine was 
also scarcely detected in former studies on other human cell lines [23-26]. The binding of 
the remaining lectins to PBMEC/C1-2 cells was notedly higher than to ECV304 cells.  
For lectin-mediated drug-delivery not only binding of the targeter but also uptake is 
desirable. Ongoing from the characterization of the sugar composition of the two cell 
lines, WGA and DBA seem to be suitable for further investigations in case of porcine 
PBMEC/C1-2 cells, whereas only WGA seems to be a promising candidate lectin for 
human ECV304 cells. For both cell lines internalization of WGA could be demonstrated 
qualitatively via fluorescence microscopy as exemplified for ECV304 in Fig. 6A and 6B. 
Ongoing from these results, enrichment of WGA within acidic compartments of the cell 
was confirmed using monensin. Since the quantum yield of fluorescein is known to be 
reduced at acidic pH and addition of monensin can compensate the pH-gradient between 
acidic compartments and the cytoplasm, the decrease of MFI during chase-incubation at 
37°C associated with a full recovery of the MFI values after addition of monensin points 
to lysosomal accumulation of the internalized lectin. As no fluorescent WGA was 
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detectable in the supernatant, it was even possible to calculate the fraction of WGA taken 
up into the cell [25]. In case of PBMEC/C1-2 cells, about 30% of initially cell bound 
lectin were internalized within 10 min, at the end of the chase incubation about 60% were 
accumulated in acidic compartments. For ECV304 cells, uptake of WGA was almost 
similar (20% after 10 min and 55% after 240 min). Furthermore, the potential of DBA as 
targeting vehicle to PBMEC/C1-2 cells could be assessed. Similar to WGA, MFI 
decreased continuously during chase incubation from 56.3 to 27.5 at 37°C. Interestingly, 
addition of monensin did not result in total recovery of the initial values. Therefore, 
possible detachment of initially membrane-bound lectin was considered, but no 
fluorescent DBA was detectable in the supernatant of the samples. Moreover, lysis of the 
cell pellets resulted in similar MFI values for both setups (4° and 37°). In addition, 
fluorescence microscopy also revealed uptake of DBA (Fig. 6C, 6D). Hence, in case of 
DBA, the quenching effects might result from an accumulation and constriction of the 
target vehicle in different, not exclusively acidic vesicular compartments of the cell. 
All in all, evaluation of the interaction between lectins and the glycocalyx of BBB 
mimicking cells demonstrated potential applicability of lectins as a tool to improve drug 
transport across the BBB. For both cell lines, accessible lectin binding sites were detected 
and the interaction of certain lectins is promising and characterized by high binding 
strength and specificity. In general, WGA seems to be a suitable candidate for lectin-
grafted drug-delivery systems in case of human ECV304 cells, whereas WGA and DBA 
seem to be promising candidate lectins for porcine PBMEC/C1-2 cells. As similar results 
to primary cells and brain sections were obtained, both cell lines can serve as models for 
lectin interaction studies in BBB research, preferentially after cultivation of monolayers.  
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TABLES 
Table 1 
Specificity of the lectins used in the competitive binding assays 
 
Lecti
n 
 
MW 
 
     Carbohydrate specificity 
 
Inhibitory sugar 
Sugar [c] in µmol/analysis 
(PBMEC/C1‐2; ECV304) 
 
WGA  36 000        GlcNAc, NANA  GlcNAc, Chitotriose  0.002‐0.063 
STL  100  
000 
      GlcNAc  GlcNAc, Chitotriose  0.016‐0.25; 0.004‐0.125 
LCA  49 000        α‐Man, α‐Glc, α‐GlcNAc  D‐Man  2‐32; 0.5‐16 
UEA‐I  63 000        α‐L‐Fuc  L‐Fuc  0.016‐0.5 
DBA  120 000        α‐D‐GalNAc, Gal  GalNAc  0.25‐4; n.d. 
PNA 
110 000 
      ß‐D‐Gal‐D‐GalNAc, ß‐D‐GalNAc, 
Gal 
D‐Gal  0.016‐0.5; 0.031‐1 
GlcNac, N‐acteyl‐D‐glucosamine; NANA, N‐acetyl‐neuraminic acid; α‐Man, α‐mannose; α‐Glc, α‐glucose; α‐L‐Fuc, α‐L‐
fucose; α‐D‐GalNAc, N‐acetyl‐α‐galactosamine; Gal, galactose; n.d.: not determined 
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Table 2 
Competitive inhibition of lectin binding (25 pmol) to confluent PBMEC/C1-2 or 
ECV304 monolayers by addition of increasing amounts of complementary carbohydrate 
 
Lectin+ 
Inhibiting sugar 
PBMEC/C1‐2 
Sugar [c] in 
µmol/reaction 
 
% inhibition 
 
IC50 
ECV304 
Sugar [c] in 
µmol/reaction 
 
% inhibition 
 
IC50 
WGA + 
Chitotriose 
0.002 
0.004 
0.008 
0.016 
0.031 
0.063 
28.19 
55.90 
68.55 
82.41 
90.33 
93.03 
0.0036  0.002 
0.004 
0.008 
0.016 
0.031 
0.063 
27.24 
59.70 
64.32 
82.42 
88.89 
94.55 
0.0034  
STL + 
Chitotriose 
0.016 
0.031 
0.063 
0.125 
0.25 
48.57 
65.16 
77.95 
82.11 
83.32 
 
0.018  0.004 
0.008 
0.016 
0.031 
0.063 
0.125 
42.85 
61.72 
74.13 
85.50 
91.99 
96.79 
0.006 
LCA + D‐Man  2 
4 
8 
16 
32 
 
41.54 
63.76 
71.19 
71.22 
82.38 
2.8  0.5 
1 
2 
4 
8 
16 
26.73 
56.81 
72.43 
83.95 
90.73 
93.12 
0.9 
UEA‐I + L‐Fuc  0.156 
0.031 
0.063 
0.125 
0.25 
0.5 
0.23 
11.16 
33.79 
45.26 
55.89 
67.57 
0.18  0.156 
0.031 
0.063 
0.125 
0.25 
0.5 
27.92 
29.17 
43.13 
68.77 
80.24 
87.34 
0.08 
DBA + GalNAc  0.25 
0.5 
1 
2 
4 
0.69 
15.32 
73.82 
83.38 
85.53 
0.8  ‐  n.d.   
PNA + D‐Gal  0.156 
0.031 
0.063 
0.125 
0.25 
0.5 
16.03 
25.26 
39.60 
48.77 
58.74 
78.65 
0.14  0.031 
0.063 
0.125 
0.25 
0.5 
1 
25.87 
41.72 
47.69 
69.64 
74.00 
80.66 
0.14 
n.d.: not determined 
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FIGURES 
 
Fig. 1: Saturation curves of lectin binding to PBMEC/C1-2 monolayers with fluorescein-
labeled lectins related to an apparent F/P ratio of 1 (mean±SD, n=4). 
 
 
Fig. 2: Comparison of the lectin-binding capacities of single cells and monolayer of 
PBMEC/C1-2 cells related to the highest binding capacity using a lectin concentration of 
25 pmol (mean±SD, n=3). 
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Fig. 3: Saturation curves of lectin binding to ECV304 monolayers grown for 4 days with 
fluorescein-labeled lectins related to an apparent F/P ratio of 1 (mean±SD, n=4). 
 
 
Fig. 4: Comparison of the lectin-binding capacities of single cells and monolayers of 
ECV304 cells related to the highest binding capacity using a lectin concentration of 25 
pmol (mean±SD, n=3). 
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Fig. 5: Mean fluorescence intensities of ECV304 cells loaded with 25 pmol WGA prior 
and after addition of monensin during incubation at 4°C and 37°C by time up to 4 h 
(mean±SD, n=3). 
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A B
DC  
Fig. 6: Fluorescence microscopy images of ECV304 cells incubated with fluorescein-
labeled WGA (25 pmol) for 240 min at 4°C (A) and 37°C (B) and PBMEC/C1-2 cells 
incubated with fluorescein-labeled DBA (25 pmol) for 240 min at 4°C (C) and 37°C (D). 
Scale bar represents 20 µm. 
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Abstract 
 
Recent studies showed that glioma conditioned medium is able to induce blood-brain 
barrier properties in brain endothelial cells in vitro. In this regard, it was investigated 
whether glioma conditioned medium can also influence the lectin-binding capacity of 
blood-brain barrier in vitro models. For the presented study cell lines PBMEC/C1-2 and 
ECV304 were chosen because it was previously shown that glioma conditioned medium 
was able to induce specific blood-brain barrier properties in these cell lines.  
Six different plant lectins (WGA, STL, LCA, UEA-I, DBA, PNA) with distinct sugar 
specificities were applied in order to elucidate the glycosylation patterns of cell line 
PBMEC/C1-2 and ECV304. Lectin-binding studies were carried out with monolayers as 
well as with single cells. In the case of PBMEC/C1-2 monolayers, results showed a 
significant increase of the binding of lectins WGA, STL, UEA-I, DBA and PNA after 
application of 25 pmol lectin when cultured in media containing soluble factors derived 
from glioma cell line C6, whereas the binding capacity for LCA remained similar. For 
ECV304 monolayers, a significant decrease of WGA, STL and LCA was observable, 
whereas UEA-I binding increased in comparison to cells grown in the corresponding 
basal growth medium without soluble C6 factors. Single cell studies showed less 
significant, but similar changes in the lectin-interactions with the cell surfaces.  
In conclusion, it was shown that soluble factors derived from glioma cell line C6 can 
modulate the “glycocalyx” of blood-brain barrier mimicking cell lines.  
 
Section: Regulatory Systems 
 
Key words: blood-brain barrier; lectins; PBMEC/C1-2; ECV304; C6; astrocytes; WGA; 
DBA; STL; PNA; UEA-I; LCA 
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1. Introduction 
 
Brain microvascular endothelial cells (BMECs) constitute the main component of the 
blood-brain barrier (BBB). The BBB maintains the homeostasis of the brain 
microenvironment which is crucial for neuronal activity and function. Unlike the 
peripheral endothelium, BMECs are characterized by the presence of tight intercellular 
junctions, minimal pinocytotic activity and the absence of fenestrations (Joo, 1996). 
Bands of tight junctions (zonula occludens) between adjacent endothelial cells restrict the 
paracellular pathway and effectively prevent the passage of polar, hydrophilic drugs 
through the endothelial cell layer, whereas in non-barrier forming capillaries the bands 
contain focal discontinuities. The resulting distinct tightness of cerebral capillary 
junctions is reflected in high transendothelial electrical resistances (TEER) (Butt et al., 
1990). 
Several recent studies have highlighted the importance of the environmental conditions to 
induce and maintain BBB properties in brain endothelial cells. Neighbouring astrocytes, 
pericytes, neurons and even the basal lamina are able to excite BBB properties. In this 
regard, different components of the extracellular matrix (ECM) as laminin, collagen IV 
and fibronectin increased barrier properties (Tilling, 1998). Recent experiments showed 
that the ECM derived from astrocytes and pericytes elevated the electrical resistance of 
cerebral endothelial cells, whereas ECM from aortic endothelial cells decreased the 
electrical resistance of the later on cultured cerebral endothelial cells (Hartmann et al. 
2007).  
In general, the surface of BMECs is covered by a dense layer of complex carbohydrates 
collectively known as the “glycocalyx”, which is supposed to contribute to the barrier 
function and can serve as target structure for novel approaches in drug delivery to the 
BBB. The glycocalyx can be characterized by the use of lectins. Lectins are plant 
proteins which can selectively bind to specific sugar residues of the cell surface. 
Stainings with lectins of cerebral endothelial cells in the 1980‘s and early 1990‘s showed 
that the lectins bound differentially on the luminal or the abluminal side of the BBB 
(Fatehi et al., 1987; Mann et al, 1992). Furthermore, lectin-staining patterns of BMECs 
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were changed after different kinds of BBB disrupting incidents. For example, a distinct 
diminution of the lectin-binding was observed on the luminal side of blood microvessels 
in cat brains after a cold-lesion injury (Vorbrodt, 1986). On the contrary, the lectin-
binding on the abluminal side of the BMEC was altered in the area of an edema. 
Moreover, translocation of the luminal receptor for Concavalin A to the abluminal side 
was observed after BBB damage in mice (Vorbrodt et al., 1984). In summary, several 
studies showed that the lectin-binding changed after alterations of the BBB functionality.  
Since it is known that astrocytes, astrocyte conditioned media (ACM), glioma cells and 
glioma conditioned media (GCM) can induce several BBB properties in endothelial cells 
as tightness and expression of specific enzymes and receptors (Janzer and Raff, 1987), 
this study aimed to investigate the possible influence of GCM derived from cell line C6 
on the lectin-binding capacity of two BBB mimicking cell lines, namely the porcine cell 
line PBMEC/C1-2 and the human cell line ECV304.  
Cell line PBMEC/C1-2 was introduced by Teifel and Friedl (1996). Typical endothelial 
markers like von Willebrand factor (vWF) and apolipoprotein A-1 as well as BBB 
markers like γ-glutamyltransferase (γ-GT) and glucose transporter GLUT-1 were 
detected in immortalized PBMEC/C1-2 (Teifel and Friedl, 1996). Furthermore, no 
differences were found in PBMEC/C1-2 between passages 91 and 198 investigating 
LDL-uptake, expression of vWF, expression of P-gP and activity of γ-GT (Suda et al., 
2001). A detailed tightness characterization of PBMEC/C1-2 cultured in different growth 
media revealed an increase of TEER induced by GCM (Neuhaus et al., 2008a). 
Moreover, PBMEC/C1-2 were used as BBB model to investigate the invasion of porcine 
brain microvascular endothelial cells by Streptococcus suis serotype 2 and by 
Haemophilus parasuis (Vanier et al, 2004 and 2006). Secondly, cell line ECV304 was 
included in the investigations. Cell line ECV304, which was introduced by Takahashi et 
al. (1990), exhibits increased TEER when co-cultured with rat C6 glioma cells (Hurst and 
Fritz, 1996; Easton and Abbott, 2002). This was confirmed by Neuhaus et al. (2008a) 
using GCM to induce an elevated TEER and an increased expression of tight junctional 
molecules in ECV304 cells. Furthermore, up-regulation of the glucose transporter 
GLUT-1 and of gamma glutamyl transpeptidase in astrocyte co-cultured ECV304 cells 
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were reported (Kuchler-Bopp et al., 1999). In addition, ECV304 developed other BBB 
characteristics including transferrin receptor expression and P-glycoprotein (P-gP) when 
co-cultured with rat glioma cell line C6 (Dolman et al., 1998). Moreover, it was shown 
by Krämer et al. (2002) that co-culture of ECV304 with glioma cell line C6 resulted in a 
change of the membrane’s lipid composition of ECV304 cells to a more in vivo like fatty 
acid pattern. ECV304 cells have also been recommended and used as a BBB in vitro 
model for drug transport studies (Garberg et al., 2005; Neuhaus et al., 2008a; Neuhaus et 
al., 2008b).  
The aim of this study was to assess the binding characteristics and specificities of several 
plant lectins with distinct carbohydrate combining facilities on these cell lines and to 
investigate whether culturing of the cells in GCM results in modified lectin-binding 
patterns. To cover a broad range of sugar structures at the cell surface, the following 
lectins were chosen: wheat germ agglutinin (WGA), Solanum tuberosum lectin (STL), 
Lens culinaris agglutinin (LCA), Ulex europaeus isoagglutinin I (UEA-I), Dolichus 
biflorus agglutinin (DBA) and peanut agglutinin (PNA). 
 
2. Results 
 
Six different lectins were chosen to characterize the glycocalyx of cell lines PBMEC/C1-
2 and ECV304 by studying monolayers as well as single cells cultured with and without 
GCM. In general, the specificity of the lectin-glycocalyx interactions was confirmed for 
monolayers as well as for single cells of both cell lines with inhibition values of more 
than 80% for each individual lectin using the corresponding competitive sugars (data not 
shown). 
 
2.1 Monolayer studies with porcine cell line PBMEC/C1-2 
The results of the lectin-concentration dependent binding experiments with PBMEC/C1-
2 monolayers grown in basal C6 medium for 4 days are shown in Fig. 1. The lectin-
binding to PBMEC/C1-2 monolayers was equally highest for WGA, LCA and DBA 
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followed by STL, PNA and UEA-I. This order of lectin-binding was constant over the 
whole concentration range with the exception of WGA that revealed higher values than 
LCA and DBA using a concentration of 100 pmol/well.  
Binding curves were also evaluated for PBMEC/C1-2 cells grown in PBMEC medium 
(glioma conditioned). Comparing the lectin-binding at 25 pmol to PBMEC/C1-2 
monolayers cultured in C6 and PBMEC medium (Fig. 2) significant differences between 
the two culture media were found. The use of the PBMEC medium significantly 
enhanced the binding capacity of WGA (185.9 ± 6.6 %), STL (156.1 ± 3.4 %), UEA-I 
(431.4 ± 19.1 %), DBA (158.7 ± 16.9 %) and PNA (139.5 ± 10.6 %), whereas the 
binding of LCA to PBMEC/C1-2 remained similar. 
 
2.2 Monolayer studies with human cell line ECV304  
The lectin-concentration dependent binding curves of ECV304 monolayers grown in 
basal ECV304 medium revealed that WGA had the highest binding capacity followed by 
STL>LCA=UEA-I>PNA>DBA (Fig. 3). The binding of DBA was hardly detectable on 
ECV304 monolayers. In addition to the comparison of the lectin-binding capacities of 
ECV304 monolayers cultured in basal ECV304 medium or in GCM of ECV304 medium, 
the influence of the cultivation time was assessed by investigating lectin-binding patterns 
of monolayers cultured for 4 or 14 days. The results of all six lectins applied at a 
concentration of 25 pmol to the monolayers after 4 or 14 days in culture either in basal 
ECV304 medium or in the GCM of ECV304 medium are summarized in Fig. 4. 
Generally, most of the lectins bound to a greater extent to the cell monolayers after 14 
days culture as compared to a cultivation time of 4 days regardless the growth medium. 
In particular, binding of WGA, STL, UEA-I, DBA and PNA to ECV304 cells grown in 
ECV304 medium was also significantly increased just as well the binding of WGA, STL, 
LCA and PNA to ECV304 cells reared in GCM of ECV304 medium. Results presented 
in figure 4 also indicate that not only the cultivation period but also the different growth 
media had an influence on the lectin-binding capacity of ECV304. For ECV304 cells 
cultured in GCM of ECV304 medium for 4 days the binding of WGA (51.2 ± 10.4 %), 
STL (75.3 ± 3.7 %) and LCA (68.9 ±13.3 %) was significantly decreased and the 
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expression of UEA-I (131.2 ± 2.4 %) was significantly increased as compared to 
ECV304 cells grown in basal medium. The binding of DBA and PNA to ECV304 cells 
cultured for 4 days was not changed by soluble factors of C6 cells. After cultivation of 
ECV304 for 14 days in GCM of ECV304 medium, the binding of WGA, STL, DBA and 
PNA was significantly decreased to 57.5 ± 5.4 % (WGA), 76.9 ± 3.8 % (STL), 26.7 ± 
18.5 % (DBA) and 64.5 ± 5.8 % (PNA) as compared to cells cultured in basal ECV304 
medium, whereas the binding capacity of LCA and UEA-I remained unchanged. 
 
2.3 Single cell studies 
Lectin-binding capacities of the two investigated cell lines PBMEC/C1-2 and ECV304 
were also assessed using single cells in order to obtain additional data about the influence 
of GCM since results can differ dependent on the method used.  
Similar to the monolayer studies concentration dependent binding curves were obtained 
between 3.125 and 100 pmol lectin for both cell lines in the appropriate growth media 
(data not shown).  
At 25 pmol the lectin-binding to PBMEC/C1-2 single cells grown in C6 medium was 
highest for DBA (8.65 ± 0.46), STL (4.07 ± 0.10) and LCA (2.50 ± 0.26) followed by 
WGA (0.25 ± 0.09), UEA-I (0.09 ± 0.01) and PNA (0.06 ± 0.01). Culturing PBMEC/C1-
2 in PBMEC medium, which contains glioma derived soluble factors, resulted in a 
similar ranking of the lectin-binding capacities: DBA (13.53 ± 0.99) > STL (3.81 ± 0.17) 
> LCA (2.02 ± 0.2) > WGA (0.33 ± 0.17) > PNA (0.28 ± 0.02) >UEA-I (0.10 ± 0.04).  
Interestingly, the binding of lectins DBA and PNA was significantly increased by 
culturing PBMEC/C1-2 cells in GCM, whereas the changes of the binding of the other 
lectins were statistically not significant. Table 2 summarizes the effects of GCM on 
lectin-binding capacities using monolayers as well as single cells for the analysis. In the 
case of PBMEC/C1-2 monolayers it was shown that the binding of WGA, STL, UEA-I, 
DBA and PNA were significantly increased. This was in contrast to the single cell studies 
where only DBA and PNA bound to a statistically significant higher extent. 
Since results of lectin-binding experiments with ECV304 monolayers were quite similar 
regardless the cultivation duration, ECV304 single cells were only analyzed after 7 days 
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in culture. The lectin-binding studies at 25 pmol to ECV304 single cells grown in 
ECV304 medium showed the following ranking: WGA (6.49 ± 0.62) exhibited strongest 
interactions followed by STL (2.12 ± 0.34), LCA (1.57 ± 0.10) UEA-I (0.09 ± 0.02) and 
PNA (0.03 ± 0.01). DBA binding was not detectable. GCM of ECV304 medium did not 
change the ranking but partly the absolute amounts of lectin-binding capacities. WGA 
interaction decreased to 80 % (5.20 ± 0.75), STL to 92 % (1.96 ± 0.50) and LCA was 
almost equal at 98 % (1.55 ± 0.02), whereas UEA-I binding increased up to 507 % (0.44 
± 0.06) and PNA to 527 % (0.17 ± 0.01). DBA binding was still not detectable. As 
indicated in table 2, single cell studies revealed only significant changes in the binding of 
WGA, UEA-I and PNA, whereas monolayer studies showed different lectin-binding 
properties of ECV304 cells for WGA, STL, LCA and UEA-I.  
 
3. Discussion 
 
Several studies showed the influence and necessity of astrocytes or their conditioned 
media for the induction of BBB properties at the BBB or for in vitro BBB models (Janzer 
and Raff, 1987; Dolman at el., 1998; Kuchler-Bopp et al., 1999). Some further reports 
revealed a change in the glycocalyx of the BBB resulting in different lectin-binding 
patterns under BBB disrupting conditions (Vorbrodt, 1986). To our best knowledge, until 
now no data have been published reporting alterations of lectin-binding patterns of BBB 
mimicking cell lines with respect to glioma conditioned medium (GCM). Thus, 
differences of the lectin-binding capacities of the two cell lines PBMEC/C1-2 and 
ECV304 induced by the usage of GCM were investigated in this study.  
The presented lectin-binding studies can be interpreted in conjunction with two aspects. 
On the one hand, lectins can be used for targeted drug delivery by increasing the uptake 
of particles or drugs into specific cells by endocytosis after binding to the cellular surface 
(Fillafer et al., 2008; Weissenboeck et al., 2004; Wirth et al., 1998). Consequently, 
possible changes of the lectin-binding might be relevant for drug delivery to the brain. 
On the other hand, because of the specificity of the lectin-binding to distinct sugar 
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moieties on the cell’s surface the lectin-binding patterns describe the compositions of the 
glycocalyx. This could be relevant for the glycobiology of the BBB in a general manner. 
For our studies two BBB mimicking continuous cell lines were selected. One main 
advantage of cell lines is that they are easier to expand and thus are more accessible for 
screening and high-throughput purposes, whereas one main disadvantage is the possible 
loss of key properties in comparison to the in vivo BBB situation or even compared to 
primary cells. We chose two cell lines, which significantly respond to astrocytic signals, 
namely the porcine PBMEC/C1-2 and the human ECV304. For example, tightness of 
monolayers of both cell lines increased after growth in GCM in comparison to layers 
cultured in the corresponding basal media (Neuhaus et al., 2008a). Several studies 
revealed the suitability of both cell lines for certain BBB studies (Easton and Abbott, 
2002; Krämer et al., 2002; Suda et al., 2001; Teifel and Friedl, 1996; Vanier et al, 2004 
and 2006). In the case of ECV304 cells, it has to be mentioned that doubt has been raised 
over the use for BBB studies and whether these cells are endothelial (Brown et al., 2000; 
Drexler et al., 2002). However, several studies have shown that BBB properties were 
inducible when ECV304 from ECACC were co-cultured with astrocytes or glioma cell 
line C6 (Hurst and Fritz, 1996; Easton and Abbott, 2002; Kuchler-Bopp et al., 1999; 
Dolman et al., 1998). Because of the fact that inducibility of BBB properties is one of the 
most important features for BBB models, we applied ECV304 cells from ECACC for our 
studies. Furthermore, ECV304 layers are able to form significantly tighter junctions as 
reflected in higher TEER values than other BBB cell lines (Tan et al., 2001; Scism et al., 
1999; Youdim et al., 2003). Moreover, it was shown that ECV304 were suitable for 
TEER dependent transport studies (Neuhaus et al., 2008b). In summary, both cell lines 
possess typical BBB properties making them adequate candidates for the presented 
studies.  
In order to determine the lectin-binding capacities of these two cell lines, studies with 
monolayers as well as with single cells were accomplished at optimized experimental 
conditions. Comparison of the PBMEC/C1-2 layers grown either in the basal C6 medium 
or the PBMEC medium containing GCM revealed significant changes in the lectin-
binding capacities. In general, the lectin-binding patterns and rankings of the monolayer 
 
1 Aims/2 Introduction/3 Specific topics/4 Conclusion/5 Appendix 
 
 
 
 
Part III: blood-brain barrier 
 
 
 136 
studies were concordant with the data of primary porcine brain endothelial cells or 
porcine brain sections (Fischer and Kissel, 2001; Plendl et al., 1996).  
Using glioma conditioned medium during cultivation, the binding of WGA, STL, UEA-I, 
DBA and PNA significantly increased, whereas binding of LCA remained similar. These 
results indicate that the accessibility of almost all corresponding sugar residues was 
elevated by the influence of glioma secreted soluble factors except for α-mannose 
(PNA). Furthermore, the 4-5 fold increase of UEA-I binding has to be emphasized which 
was maybe due to a predominant increase of α-fucose on the cellular surface.  
As an additional method lectin-binding studies to single cells were performed. The main 
advantage of this method using a flow cytometer is the quantitative measurement of the 
lectin-binding to each single cell. In contrast to the monolayer studies, it was possible to 
prove that lectins had bound to the single cells uniformly and that it was not a randomly 
distributed binding only to a part of the total cell collectivity. In general, lectin-
interaction studies with monolayers corresponded better to results obtained with primary 
endothelial cells and cortical brain section than single cell experiments did (Fischer and 
Kissel, 2001; Plendl et al., 1996). In this context, it has to be mentioned that the absolute 
numbers of the lectin-binding capacities obtained by the two methods are not to be 
compared since cells had been treated in different ways before the data acquisition. 
However, single cell studies revealed no contradicting results to the data of the 
monolayer tests. DBA and PNA binding increased significantly as compared to the 
monolayer studies, whereas for all other lectins no significant change was detectable. 
Long-term studies with PBMEC/C1-2 were not realized since these cells start detaching 
after 5 days culture at the confluent status (Neuhaus et al., 2008a).  
In the case of the human cell line ECV304, binding of WGA, STL and LCA onto the 
layers was lowered after 4 days cultivation in the GCM as compared to layers grown in 
the corresponding basal medium, whereas UEA-I significantly increased. Interestingly, 
UEA-I was reported as a cerebral endothelial marker, which binds to human, rat and 
porcine brain endothelial cells, but not to goat, dog or mouse (Fatehi et al., 1987; Abbott 
et al., 1992; Vorbrodt and Trowbrige, 1991; Vorbrodt et al., 1986). Moreover, several 
hints were published that especially α-fucose, which interacts with UEA-I, plays an 
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important role during alterations at the BBB (Mann et al., 1992). In concordance with our 
results that UEA-I binding was elevated by GCM onto monolayers of both cell lines, it is 
suggested that UEA-I can be used as a distinct marker of the BBB unlike WGA which is 
capable to bind onto surfaces of various different cell types (Gabor et al., 2001; Plattner 
et al., 2008; Toegel et al., 2007; Wirth et al., 2002). In the context of drug targeting, 
WGA enabled the transport of the enzyme horseradish peroxidase into the brain (Banks 
et al., 1994). However, the usability of UEA-I for lectin-based drug targeting has to be 
evaluated.  
ECV304 layers were also grown for 14 days, since these cells differentiate further with 
time (Neuhaus et al., 2008a). Comparable to the lectin-binding on ECV304 after 4 days 
culture, a similar, medium dependent decrease of WGA and STL binding was observed. 
This might be due to a decrease of N-acetyl- D-glucosamine structures. Interestingly, 
after 14 days of culture the binding of LCA and UEA-I onto ECV304 monolayers was 
not influenced by GCM, whereas DBA and PNA binding decreased as compared to cells 
reared in the corresponding basal medium. Besides the qualitative differences of lectin 
binding onto ECV304 layers with respect to the different growth media, the binding of 
almost all lectins after 14 days cultivation (except LCA on ECV304 layers reared in 
ECV304 medium and DBA on ECV304 layers grown in GCM of ECV304 medium) was 
higher than interactions of the lectins with ECV304 layers after 4 days in culture. This 
further clearly indicates the influence of the differentiation status of the cell layers on the 
outcoming results.  
Single cell studies with ECV304 after 7 days culture (see table 2) revealed also some 
medium dependent, significant differences. For example, WGA binding was decreased to 
80 %, whereas UEA-I and PNA binding was increased up to 507 and 527 %. 
Interestingly, the increase of the binding of UEA-I and the decreased WGA interaction 
was in concordance with the results of the ECV304 monolayer studies.  
However, comparing the effects of GCM on the lectin-binding capacities of the two cell 
lines, it is noticeable that in the case of porcine cell line PBMEC/C1-2 only increases of 
the lectin-bindings were observed, whereas in the case of human cell line ECV304 most 
of the lectin-cell interactions decreased compared to cells cultured in basal growth 
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medium. Considering these different effects the feasibility of the used cell lines for e.g. 
the development of drug targeting strategies has to be discussed. Generally, the human 
cell line ECV304 is suggested to be the more predictive model for the human situation. 
In particular, this was for example supported by the lectin-binding data of DBA. DBA 
bound to a significantly greater extent to porcine cell line PBMEC/C1-2 than to human 
ECV304. This was in concordance with other studies, which showed significant DBA 
binding to porcine primary brain endothelial cells, but negligible interaction with human 
primary as well as human tumor cells from several tissues (Fischer and Kissel, 2001; 
Plendl et al., 1996; Plattner et al., 2008; Toegel et al., 2007). Moreover, Mann et al. 
(1992) investigated the lectin histochemistry of human cerebral microvessels in 
Alzheimer’s disease and concluded that DBA bound only to the basal membrane and not 
to the endothelial cells themselves. Thus, the weak interaction of DBA with ECV304 
cells is one supporting evidence for the superior feasibility of cell line ECV304 in 
comparison to the porcine cell line PBMEC/C1-2 to mimic the human situation. 
However, cell line ECV304 will certainly exhibit also some changed qualities compared 
to human primary brain endothelial cells. Thus, effects of GCM on the glycocalyx of 
human primary brain endothelial cells may differ to the presented findings with the cell 
lines. Furthermore, although it was shown in several reports that glioma cell line C6 
induce BBB properties in brain endothelial cells, the influence of primary glial cells may 
lead to more distinct differences in the lectin-binding patterns than glioma conditioned 
medium does (Boveri et al., 2005; Smith et al., 2007). 
In conclusion, it was shown for the first time that the glycocalyx of BBB mimicking cell 
lines can be modulated by soluble factors derived from glioma cell line C6 demonstrating 
that alterations of BBB properties can be induced by the environment, in particular by 
astrocytes. Until now, it is still unknown whether new and/or additional glycoproteins 
had been recognized by the lectins or the accessible number of already present sugar 
structures was increased due to the application of GCM. In this context, correlation of 
lectin studies with other biochemical techniques is necessary (Fatehi et al., 1987). 
However, based on the presented data it is suggested that astrocytes or astrocytic soluble 
factors can modulate the sugar patterns of the glycocalyx of the BBB. This seems quite 
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important in the context of BBB altering (e.g. during aging, Alzheimer’s disease) or 
damage (e.g. during stroke) and emphasizes the generally growing importance of 
glycobiology in physiological processes in particular at the BBB.  
 
4. Experimental procedures 
 
4.1 Materials 
Amphotericin B, transferrin and gelatin were bought from Sigma (St. Louis, MO, USA), 
Medium199 (M199), Iscove’s modified Dulbecco’s medium (IMDM), Ham reg. nutrient 
mixture F12 (Ham’s F-12), newborn calf serum (NCS), foetal calf serum (FCS), L-
glutamine and penicillin/streptomycin were obtained from Invitrogen Life technologies 
(Gibco TM, Carlsbad, CA, USA). Heparin was purchased from Fluka (Buchs, 
Switzerland). The fluorescein-labeled lectins and their carbohydrate specificities are 
listed in Table 1. All lectins were bought from Vector Laboratories (Burlingame, USA) 
and contained >98 % active conjugate and no free fluorescein. The molar ratio 
fluorescein/protein (F/P) was 2.9 in the case of wheat germ agglutinin (WGA), 3.1 for 
Solanum tuberosum lectin (STL), 3.8 for Lens culinaris agglutinin (LCA), 2.7 for Ulex 
europaeus isoagglutinin I (UEA-I), 2.2 for Dolichus biflorus agglutinin (DBA) and 4.7 
for peanut agglutinin (PNA). Cell culture flasks and 96-well plates were purchased from 
Greiner Bio-one (Kremsmünster, Austria). 
 
4.2 Cell culture 
Cell line PBMEC/C1-2 was a kind gift from Teifel and Friedl (1996) and was cultured in 
basal C6 medium and PBMEC medium (50 % C6, 50 % GCM of C6 medium) at 
passages 61-90. The ECV304 cell line was purchased from the European Collection of 
Cell Cultures (ECACC, Wiltshire, UK) and was maintained in basal ECV304 medium 
and GCM of ECV304 medium at passages 142-164.  
The C6 medium is a 1:1 mixture of Ham’s F12 and IMDM supplemented with 7.5 % 
(v/v) NCS, 7 mM L-Glutamine, 5 µg/ml transferrin, 0.5 U/ml heparin, 100 U/ml 
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penicillin, 100 µg/ml streptomycin and 0.25 µg/ml amphotericin B. The basal ECV304 
medium is made of M199 containing 10 % (v/v) FCS, 2 mM L-glutamine, 100 U/mL 
penicillin, 100 µg/mL streptomycin, and 0.25 µg/mL amphotericin B. In order to obtain 
GCM of C6 and GCM of ECV304 medium, rat C6 glioma cells obtained from the 
German Cancer Research Center (DKFZ, Heidelberg, Germany) were cultured in C6 and 
ECV304 medium, respectively, and the supernatant was collected every other day 
(Neuhaus et al., 2008a). All cells were cultured at 37°C, 5 % CO2 and 96 % humidity.  
 
4.3 Evaluation of the lectin-binding capacity 
Lectin-binding capacities were assessed with monolayers as well as with single cells.  
For monolayer studies, cells were seeded on gelatin-coated 96-well plates at a 
concentration of 80 000 cells/cm2 and grown to confluence. Monolayers were used on 
day 4 (PBMEC/C1-2, ECV304) and 14 (ECV304 only) after seeding. They were washed 
twice with 150 µl PBS per well prior to incubation with 50 µl of the respective lectin in 
PBS (3.125-100 pmol, serial dilution) for 20 min at 4°C. Excessive lectin was removed 
by washing the monolayers with 150 µL PBS twice. Then, 50 µl PBS were added and the 
mean fluorescence intensity (MFI) of each well was measured using a fluorescence 
microplate reader (Infinite M200, Tecan, Grödig/Salzburg, Austria). Negative controls 
were prepared similarly using PBS instead of lectin solution. Blank studies without cells 
showed negligible lectin-binding on the gelatin coating.  
For single cell studies cells were seeded on gelatin-coated culture flasks and grown to 
confluence. 4 (PBMEC/C1-2) and 7 (ECV304) days after seeding, cells were harvested 
by trypsinization, centrifuged (1000 g, 4°C, 10 min) and resuspended in the respective 
fresh medium. The number of single cells was quantified by microscopy and adjusted to 
6x106 cells/ml. 50 µl of the cell suspension were mixed with 50 µl of a solution of the 
particular lectin in PBS (3.125-100 pmol, serial dilution). In order to estimate the 
autofluorescence of the cells, control samples with unlabeled cells were included in all 
experiments. After incubation for 5 min at 4°C cells were collected by centrifugation 
(1000 g, 4°C, 5 min) and washed twice with 150 µl PBS to remove any unbound lectin. 
Afterwards the cell suspension was diluted with 1 ml particle free PBS in order to 
 
1 Aims/2 Introduction/3 Specific topics/4 Conclusion/5 Appendix 
 
 
 
 
Part III: blood-brain barrier 
 
 
 
 141 
provide a single cell suspension suitable for flow cytometric analysis. Data acquisition 
was performed using an Epics XL-MCL analytical flow cytometer (Coulter, USA). 3000 
cells per sample were accumulated and the single cell population was gated using the 
forward versus side scatter signals excluding cell aggregates and debris. Fluorescence 
emission was detected at 525 nm (10 nm bandwith) after excitation at 488 nm. 
Amplification of the fluorescence signal was adjusted to put the autofluorescence signal 
of unlabeled cells in the first decade of the four-decade log range. Data analysis was 
carried out using Coulter System II software 3.0. For further calculations, the mean 
channel number of the logarithmic fluorescence intensities of individual peaks (MFI) was 
used.  
As the lectins show different molar fluorescein/protein (F/P) ratios, the results of all 
experiments expressed as mean cell-bound fluorescence intensities were related to an 
apparent conjugation number of 1 mol fluorescein per mole lectin to guarantee 
comparability. 
The specificity of the lectin-binding capacities was verified by competitive inhibition 
with appropriate carbohydrates according to the method reported by Plattner et al. 
(2008).  
 
4.4 Statistics 
All experiments were carried out at least in triplicate. Data are presented as mean ± S.D. 
Statistics were performed using a two sided student’s t-test based on different variances. 
Probabilities for significant differences are given in the according figure legends. 
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Tables 
 
Table 1: Specificity of the lectins used in the binding assays 
 
Lectin 
 
MW 
 
     Carbohydrate specificity 
 
Inhibitory sugar 
WGA 36 000       GlcNAc, NANA GlcNAc, Chitotriose 
STL 100  000       GlcNAc GlcNAc, Chitotriose 
LCA 49 000       α-Man, α-Glc, α-GlcNAc D-Man 
UEA-I 63 000       α-L-Fuc L-Fuc 
DBA 120 000       α-D-GalNAc, Gal GalNAc 
PNA 110 000       ß-D-Gal-D-GalNAc, ß-D-GalNAc, Gal D-Gal 
GlcNac, N-acteyl-D-glucosamine; NANA, N-acetyl-neuraminic acid; α-Man, α-mannose; α-Glc, α-glucose; 
α-L-Fuc, α-L-fucose; α-D-GalNAc, N-acetyl-α-galactosamine; Gal, galactose.  
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Table 2: Alteration of lectin-binding capacities of porcine PBMEC/C1-2 and human 
ECV304 cells grown in the glioma conditioned media as compared to cells cultured in 
the corresponding basal media.  
 
 WGA STL LCA UEA-I DBA PNA 
PBMEC/C1-2 cells       
Monolayer, 4 days + + n.s.  ++ + + 
single cells n.s.  n.s.  n.s.  n.s.  + ++ 
       
ECV304 cells       
Monolayer, 4 days - - - + n.s. n.s.  
single cells - n.s. n.s. ++ n.d. ++ 
Statistical significances (at least p <0.05) were determined by a two sided student‘s t-test with different 
variances. The differences in the lectin-binding were described by following legend: ++ = increase over 
200 %, + = increase to 100-200 %, - = decrease to 50-100 %, -- = decrease lower than 50 %; n.s. = not 
statistically significant, n.d. = not detectable. 
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Figures 
 
 
Fig. 1 Concentration dependent binding curves of lectin-binding to PBMEC/C1-2 
monolayers cultured in basal C6 medium for 4 days. The fluorescein-labeled lectins were 
related to an apparent F/P ratio of 1. Data represent mean ± SD (n = 3-4). 
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Fig. 2: Comparison of the lectin-binding capacities of PBMEC/C1-2 cells grown in C6 
(control) or PBMEC medium (1:1 C6 and GCM of C6 medium) for 4 days using 25 pmol 
of fluorescein-labeled lectins, incubation: 20 min, 4°C; Data represent mean ± SD, 
statistical significant differences were determined by student‘s t-test: *=p<0.05, 
**=p<0.01, ***=p<0.005 (n=3-7). 
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Fig. 3: Concentration dependent binding curves of lectin-binding to ECV304 monolayers 
cultured in basal ECV304 medium for 4 days. The fluorescein-labeled lectins were 
related to an apparent F/P ratio of 1. Data represent mean ± SD (n = 3-6).  
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Fig. 4 Comparison of the lectin-binding capacities of ECV304 layers grown in ECV304 
or GCM of ECV304 medium for either 4 days or 14 days using 25 pmol of fluorescein-
labeled lectins, incubation: 20 min, 4°C; Data represent mean ± SD. Statistical significant 
differences were determined by student‘s t-test: **=p<0.01, ***=p<0.005 (n=3-7). 
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Abstract 
In the present study human monocytic THP-1 cells were treated with phorbol 12-
myristate 13-acetate (PMA) in order to obtain macrophage-like cells. Before and after 
treatment, plant lectins with distinct sugar specificities were applied in order to elucidate 
the glycosylation pattern of both cell types and to follow changes during differentiation. 
As a result of flow cytometric analyses, for untreated as well as for differentiated cells 
wheat germ agglutinin (WGA) yielded the highest binding rate without significant 
changes in the binding capacity. For the other lectins divergent results were obtained 
which point to reorganization of sugar residues on the cell surface during differentiation.  
Additionally, cytoinvasion being beneficial for targeted drug delivery was studied with 
WGA which had displayed a high binding capacity together with a high specificity. For 
both cell types decreased fluorescence intensity at 37°C as compared to 4°C was 
observable pointing to internalization and accumulation within acidic compartments. 
Thus, WGA-functionalized PLGA nanoparticles were prepared and their uptake 
evaluated. 
Uptake rates of 55% in case of PMA treated cells suggested that WGA-grafted drug 
delivery systems might be an interesting approach for treatment of infectious diseases 
provoked by parasites, facultative intracellular bacteria or viruses such as HIV. 
 
 
 
Key words: Monocytes/macrophages; glycosylation pattern; lectins; bioadhesion; drug 
targeting; nanoparticles 
 
 
 
 
 
1 Aims/2 Introduction/3 Specific topics/4 Conclusion/5 Appendix 
 
 
 
 
Part IV: monocytes/macrophages 
 
 
 
 157 
Introduction 
Being essential parts of the immune system monocytes and macrophages are involved in 
defense against microbial infection, initiation of inflammation, immunity to foreign 
substances, wound healing, and angiogenesis. They originate from the bone marrow and 
undergo differentiation from hematopoetic stem cells to blood monocytes and finally to 
tissue-specific macrophages. Like all eukaryontic cells, they are covered by a 
carbohydrate-rich layer, denominated glycocalyx or pericellular matrix [1, 2]. This cell 
coat is several tens of nanometers thick and is of functional importance as the first line 
defense of the innate immune system is relying on recognition of carbohydrates [3]. 
Furthermore, it plays an important role in cell-cell and cell-matrix interactions. At this, 
there is evidence that glycocalyx elements influence the endocytic capacity of monocytes 
[4] and are modulated during adhesion [5,6]. As adhesion of peripheral blood monocytes 
to endothelial cells initiates the differentiation program of monocytes into phagocytes 
[7], this process may also cause reorganization of sugar residues at the cell surface.  
To investigate the glycosylation pattern of monocytes, which undergo differentiation to 
macrophages, the human monocytic leukemia cell line THP-1 was chosen, which was 
established by Tsuchiya et al. and exhibits stable monocytic characteristics [8]. 
Additionally, treatment with various agents such as DMSO, phorbol 12-myristate 13-
acetate (PMA), 1, 25-dihydroxyvitamin D3, retinoic acid or cytokines results in 
differentiation along the monocytic lineage [9-11]. In summary, it was shown that 
macrophage-like cells, which mimic native monocyte-derived macrophages in several 
aspects, are obtained with phorbol esters [12], whereas DMSO or retinoic acid shift the 
cells rather to characteristics of neutrophils [13]. 
In the present study, differentiation was carried out with PMA according to Park et al. 
[14]. In comparison to primary human monocytes, THP-1 cells are characterized by 
homogeneity, accessibility and a higher transfection efficiency which renders them a 
reliable cell model. 
To identify and characterize the glycocalyx elements of both untreated and differentiated 
THP-1 cells, binding of fluorescent-labeled lectins was investigated. Lectins represent 
carbohydrate binding proteins which recognize distinct sugar structures at the cell 
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surface. In order to cover a broad range of sugar residues at the cell surface several plant 
lectins with diverse carbohydrate specificities were applied: Wheat germ agglutinin 
(WGA) and Solanum tuberosum lectin (STL) were used to identify N-acetyl-D-
glucosamine structures and in case of WGA also sialic acid residues. The lectin from 
Sambucus nigra (SNA) specifically recognizes sialic acid (2, 6)Gal/GalNAc sequences, 
and Lens culinaris agglutinin (LCA) binds to mannose residues. Peanut agglutinin (PNA) 
was used to detect galactosamine moieties, Dolichus biflorus agglutinin (DBA) for N-
acetyl-D-galactosamine-containing structures, and Ulex europaeus isoagglutinin I (UEA) 
specifically binds to fucose.  
Ongoing from this characterization and comparison of the pericellular matrices of both 
cell types, the internalization of WGA was studied in detail. This lectin had already been 
shown to enhance the phagocytic and bactericidal activity of murine peritoneal 
macrophages [15], and hence might be a suitable candidate for drug targeting purposes. 
As site-specific drug delivery promises higher therapeutic efficiency together with a 
reduction of side effects, there are considerable efforts to identify appropriate targeters 
which can be used for the functionalization of drug delivery devices. Therefore, 
nanoparticles were prepared from the biocompatible and biodegradable polymer 
poly(DL-lactide-co-glycolide) (PLGA) and surface-modified with WGA [16]. 
Subsequently, their interaction with untreated and differentiated THP-1 cells was studied 
in order to examine the potential of WGA for targeting nanoparticles to macrophages.  
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Materials and methods 
Chemicals 
Fluorescein-labeled lectins from Triticum vulgare (wheat germ agglutinin (WGA); molar 
ratio fluorescein/protein (F/P)=2.9), Solanum tuberosum (STL; F/P=3.1), Sambucus 
nigra (SNA, F/P=7.2), Lens culinaris (LCA; F/P=3.8), Arachis hypogaea (peanut 
agglutinin (PNA); F/P=5.2), Dolichos biflorus (DBA; F/P=2.2) and Ulex europaeus 
(UEA; F/P=2.7) were purchased from Vector laboratories (Burlingame, CA, USA). For 
the immunofluorescence analysis, FITC-labeled antibodies were obtained from Beckman 
Coulter (Krefeld, Germany). For particle preparation, poly(DL-lactide-co-glycolide) 
RESOMER® RG 503 H (PLGA) was purchased from Boehringer Ingelheim (Ingelheim, 
Germany). 
All other chemicals were purchased from Sigma (St. Louis, MO, USA) unless other 
specified. 
 
Cell culture 
Human THP-1 monocytic leukemia cells were obtained from the American Type Culture 
Collection (Manassas, VA, USA). Cells were seeded at a density of 1x105 cells/ml in 
RPMI-1640 medium containing 10% heat-inactivated FCS (Biochrom AG, Berlin, 
Germany), 200 mM L-glutamine and 104 U/ml penicillin, and 104 µg/ml streptomycin 
and maintained at 3-8x105 cells/ml in a humidified atmosphere with 5% CO2 at 37°C.  
Differentiation into macrophages was achieved by resuspending the cells at 
3x105cells/ml in growth medium supplemented with phorbol-12-myristate-13-acetat 
(PMA; 8 nM in DMSO) for 48 h. To analyse the surface marker CD14 by 
immunofluorescence, cells were incubated with PMA also for 24 h and 72 h.  
Viability of the cells was determined by trypan blue exculsion and counting the viable 
cells using a Bürker-Türk hemocytometer. Adherence of differentiated cells was 
examined with the same setup by determining the amount of unattached and adherent 
cells. Unattached cells were collected by centrifugation (1000 rpm, 5 min, 4°C) of the 
supernatant, whereas adherent cells were detached with 0.25% EDTA in PBS followed 
by centrifugation. 
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Immunofluorescence analysis of surface antigen CD14  
Untreated THP-1 cells were harvested by centrifugation (1000 rpm, 5 min, 4°C) and 
resuspended in RPMI medium at a concentration of 5x106 cells/ml. 
Differentiated cells were detached and collected as described above and re-suspended at 
the same concentration as untreated cells.  
50 µl cell suspension (5x106 cells/ml) were incubated with 210 µl of the FITC-labeled 
anti-human CD14 monoclonal antibody solution (MY4-FITC, diluted 1:20 in PBS with 
2% FCS) for 30 min at 4°C. After incubation, cells were spun down (1000 rpm, 5 min, 
4°C) and the supernatant was discarded. Then, 100 µl PBS were added, and this washing 
step was repeated to remove any unbound antibody. Finally, cells were re-suspended in 1 
ml particle free PBS, and the mean cell-associated fluorescence intensity (MFI) was 
determined by flow cytometry (Epics XL-MCL, Coulter, FL, USA).  
To detect any non-specific antibody binding, additional cells were treated with an 
adequate isotypic control (MsIgG2b-FITC) or with PBS before analysis. 
 
Lectin binding capacity 
Untreated and differentiated cells were harvested as described above and processed 
immediately. 50 µl cell suspension (5x106 cells/ml) were incubated with a dilution series 
of fluorescein-labeled lectins (3.125-100 pmol in PBS, 50 µl) for 15 min at 4°C. Then, 
cells were washed and prepared for flow cytometry as described above. Negative controls 
containing PBS instead of the lectin solution were included in all experiments and 
considered for all calculations. As a control to estimate non specific-binding, samples 
were prepared as above but using a dilution series of fluorescein-labeled bovine serum 
albumin (BSA, (F/P=10)) instead of the lectins. 
 
Specificity of the lectin binding  
To determine if the binding of the lectins is mediated by carbohydrate moieties at the 
surface of untreated and differentiated THP-1 cells, 50 µl cell suspension (5x106 
cells/ml), 100 µl of a dilution series of the corresponding complementary carbohydrate 
and 50 µl of a solution containing 12.5 pmol fluorescein-labeled lectin were incubated 
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for 15 min at 4°C. The subsequent processing was again performed as described above. 
Table 1 displays the respective inhibitory carbohydrate for each lectin and the amounts 
used in the study. According to preliminary results, UEA-I and DBA exhibited no 
binding to either of the cell lines. Hence, no specificity studies were carried out for these 
lectins. The specificity of the interaction between SNA and THP-1 cells was not 
determined as the corresponding carbohydrate sialic acid α2,6 Gal/GalNAc is 
commercially unavailable.  
 
Internalization of surface bound WGA 
To evaluate the internalization of surface bound WGA, 50 µl cell suspension (5x106 
cells/ml) of untreated and differentiated cells were incubated with 50 µl WGA solution 
containing 12.5 pmol lectin for 15 min at 4°C (pulse incubation). Unbound lectin was 
removed by centrifugation and washing with 150 µl PBS. Subsequently, cells were 
further incubated for 0-240 min at either 4°C or 37°C (chase incubation) and then 
prepared for flow cytometry. After determination of the mean fluorescence intensity 
(MFI), 40 µl monensin solution (2.4 mM in EtOH) were added and cells were incubated 
for 3 min at room temperature. Finally, the MFI was assessed again.  
 
Preparation of WGA-functionalized nanoparticles 
Nanoparticles were prepared by the solvent evaporation technique. Briefly, 400 mg of 
PLGA were dissolved in 2 g ethyl acetate. Upon addition of 6 ml 10 % (w/w) aqueous 
solution of Pluronic® F68, the organic phase was dispersed in the aqueous phase by 
ultrasonication for 50 s (Bandelin electronic Sonopuls UW 70/HD 70, tip MS 72/D, 
Berlin, Germany). The resulting O/W emulsion was poured into 100 ml 1 % (w/w) 
aqueous solution of Pluronic® F68. The organic solvent was allowed to evaporate at 
room temperature during mechanical stirring (600 rpm) at atmospheric pressure for 1 h 
and subsequently during 1 h under reduced pressure.  
The PLGA nanospheres were covalently coupled with fluorescein-labeled WGA or 
fluorescein-labeled BSA. For this purpose, 40 ml of the particle suspension were 
activated by addition of 480 mg  N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
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hydrochloride (EDAC) and 20 mg N-Hydroxysuccinimide (NHS), each dissolved in 1 ml 
20 mM HEPES/NaOH buffer pH 7.4. After end-over-end incubation for 2 h at room 
temperature the suspension was washed twice by diafiltration (Vivaflow 50, 100 000 
MWCO PES, Sartorius Vivascience GmbH, Goettingen, Germany) using 80 ml of 0.1% 
Pluronic in 20 mM HEPES/NaOH pH 7.4. The nanoparticle suspension was divided into 
two equal parts followed by addititon of 20 nmol of WGA (0.72 mg) and BSA (1.32 mg), 
respectively, each dissolved in 1 ml of the same buffer as above. Following end-over-end 
incubation overnight at room temperature non-reacted coupling sites were saturated by 
addition of 300 mg glycine to each tube and further incubation for 1 h. Finally, excess of 
reagents was removed by three cycles of diafiltration with 40 ml of 0.1% Pluronic in 20 
mM isotonic HEPES/NaOH pH 7.4 each. The amount of fluorescein-labeled protein 
coupled to the particle surface was determined by fluorimetric analysis following 
dissolution of an aliquot in 0.1M NaOH. The respective nanosphere suspensions 
contained 3.9 µg/ml WGA and 2.2 µg/ml BSA coupled to the particle surface. The mean 
particle size as determinded by dynamic light scattering (Zetasizer Nano ZS, Malvern 
Instruments Ltd., UK) was 160.3 nm for WGA-functionalized nanospheres with a 
polydispersity index (PDI) of 0.130 and 151.2 nm for BSA-coated nanospheres with a 
PDI of 0.133.  
 
Internalization of surface bound WGA-functionalized PLGA nanoparticles 
In order to examine the interaction between WGA- or BSA-coupled PLGA nanospheres 
and untreated as well as differentiated THP-1 cells, 50 µl cell suspension (5x106 cells/ml) 
were incubated with 50 µl nanoparticle suspension for 15 min at 4°C (pulse incubation). 
Unbound particles were removed as described above, and the cells were further incubated 
for 30, 60 or 120 min at either 4°C or 37°C (chase incubation). After a first flow-
cytometric analysis, 40 µl monensin (2.4 mM in EtOH) were added. Thereupon, cells 
were incubated for 3 min at room temperature, and the MFI values were determined 
again.  
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Flow cytometry  
Data were acquired using an Epics XL-MLC analytical flow cytometer (Coulter, FL, 
USA). In order to exclude any dead cells, debris, and aggregates, viable cells were gated 
according to their forward versus side scatter properties. From each sample, 3 000 cells 
were accumulated within this gate. Fluorescence emission of the fluorescence labeled 
single cell-population was measured at 525 nm (10 nm bandwidth) after excitation at 488 
nm. Data analysis was conducted using Coulter System II Software 3.0. 
 
Fluorescence microscopy 
Uptake of WGA-functionalized PLGA nanoparticles was visually confirmed by 
incubating 50 µl cell suspension (5x106 cells/ml, both untreated and differentiated cells) 
with 50 µl nanoparticle suspension for 15 min at 4°C (pulse incubation). After removal 
of unbound particles as described above, the cells were further incubated for 120 min at 
37°C. Thereafter, cells were washed again and immediately mounted for microscopy 
without fixation. Control samples were incubated at 4°C only. 
Immunfluorescence images were obtained using a Nikon Eclipse 50i microscope 
equipped with an EXFO X-Cite 120 fluorescence illumination system. Excitation and 
emission filter blocks were at 465-495/515-55 for green fluorescence and 510-560/>590 
for red fluorescence. Fluorescence images were acquired at 40x magnification and 
processed using Lucia G v5.0 software for image evaluation.  
 
Statistics 
Statistical analyses were carried out using the Microsoft Excel® integrated analysis tool. 
The hypothesis test among two data sets was made by comparing two means from 
independent (unpaired) samples (t-test). Values of p<0.05 were considered significant. 
All experiments were performed at least in triplicate.  
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Results 
PMA-induced differentiation of THP-1 monocytes to macrophages 
After treatment of THP-1 cells with 8 nM PMA for 48 h, adherence and morphology 
were examined microscopically. Analysis of cell adherence by counting after trypan blue 
exclusion revealed that >90% of the cells were attached to the surface after PMA-
treatment. Additionally, adherent THP-1 cells were more flattened and elongated 
indicating the macrophage phenotype as compared to the untreated cells which remained 
round and in suspension albeit partly aggregated in clusters.  
To further ensure differentiation to macrophages, CD14 expression was investigated as 
the up-regulation of this surface molecule has been reported for maturating monocytes 
[10,17]. Flow cytometric analysis revealed an increase of CD14 as compared to untreated 
THP-1 cells. The mean cell-associated fluorescence intensity (MFI) was 0.5 ± 0.3 in case 
of untreated cells, 0.8 ± 0.0 MFI for cells treated for 24 h, 9.9 ± 0.5 for cells treated for 
48h, and 26.0 ± 0.5 MFI in case of cells treated for 72 hours. MFI values of the isotype 
control were 0.52 in case of untreated cells and 0.57 in case of differentiated cells and 
subtracted from all data quoted.  
 
Lectin binding capacity of THP-1 cells 
Plant lectins with different carbohydrate specificities were used to estimate the 
glycosylation pattern of untreated and differentiated THP-1 cells. For comparison of the 
data, MFI values of each lectin were related to an apparent conjugation number of 1 mol 
fluorescein per mole lectin. For both, untreated and differentiated THP-1 cells WGA 
yielded the highest binding capacity with MFI values between 1.0 ± 0.0 and 17.1 ± 0.2 
(untreated cells) and 0.7 ± <0.1 and 16.6 ± 0.4 (differentiated) respectively (Fig. 1). In 
case of untreated THP-1 cells, lectin binding was also observed for STL (MFI values up 
to 10.3 ± 0. 5), PNA (up to 1.0 ± 0.1) and SNA (up to 0.3 ± <0.1) (Fig. 1A). LCA 
revealed only very low MFI values scarcely above the autofluorescence of the cells (0.1 
± <0.1). For both cell types, binding of UEA-I, DBA as well as BSA, which served as a 
control for non-specific protein-membrane interactions, were not detectable. Comparison 
of the two different THP-1 types exhibited for differentiated THP-1 cells also a distinct 
 
1 Aims/2 Introduction/3 Specific topics/4 Conclusion/5 Appendix 
 
 
 
 
Part IV: monocytes/macrophages 
 
 
 
 165 
interaction with STL (MFI values up to 5.8 ± 0.2) and SNA (1.2 ± <0.1) (Fig. 1B). 
Interestingly, a notedly higher interaction occurred with LCA (2.4 ± <0.1 MFI at 100 
pmol) as compared to untreated THP-1 cells, whereas no binding of PNA was observed. 
Fig. 2 compares the results at a lectin concentration of 100 pmol. At this concentration, 
no significant differences (p>0.05) were evaluated for WGA, as contrary to all other 
lectins (p<0.01).  
 
Specificity of the lectin-THP-1 interaction 
The specificity of the interaction between the plant lectins and THP-1 cells was 
elucidated by competitive inhibition with complementary carbohydrates (Table 1). For 
both untreated and differentiated cells, addition of increasing amounts of corresponding 
carbohydrates resulted in a decrease of the cell-bound lectin. The results are shown 
exemplarily for differentiated cells in Fig. 3 and indicate the specificity of the lectin-cell 
interactions. Based on the control sample without any sugar addition representing 100%, 
the percentage of inhibition was calculated. At this, inhibition values of more than 85% 
were calculated for WGA, STL, and LCA which points to a highly specific interaction of 
the respective lectin with cellular structures. In case of untreated cells, similar results 
were obtained for WGA and STL with inhibition values of about 90% in the same 
concentration range (data not shown). As LCA had not shown a relevant binding capacity 
to untreated THP-1, the specificity of the PNA-cell interaction was assessed instead, 
which also turned out to be specific as represented by more than 90% inhibition at a 
concentration of 1 µmol galactosamine/reaction (data not shown).  
 
Internalization of surface bound WGA 
Fig. 4 depicts the results of the internalization experiments with differentiated THP-1 
cells. After pulse incubation at 4°C, the MFI values of surface-bound WGA amounted to 
41.5 ± 0.9 at the mean. During chase incubation at 37°C, a time-dependent decrease in 
fluorescence intensities was observed resulting in 15.8 ± 0.5 MFI after 240 min. In case 
of undifferentiated THP-1 cells (data not shown), MFI values yielded 40.6 ± 2.0 after 
pulse incubation and decreased to 14.2 ± 1.1 upon incubation at 37°C for 240 min. After 
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adding monensin to these WGA pretreated cells, the reduced fluorescence intensity was 
restored and approached the same level as the control samples at 4°C.  
In addition, the same assays were performed for both cell lines also at 4°C where no 
considerable differences between the MFI values prior and after monensin addition were 
observable.  
 
Interaction of WGA-functionalized nanoparticles with THP-1 cells  
To investigate a potential applicability of lectins for targeting drugs to macrophages the 
interaction of WGA-functionalized nanoparticles with THP-1 cells was studied. After a 
pulse incubation at 4°C and removal of unbound particles, the chase incubation was 
performed up to 120 min at 4°C and 37°C. During chase incubation of untreated cells at 
37°C, MFI values decreased from 9.1 ± 0.4 (0 min) to 6.0 ± 0.1 (120 min). Upon addition 
of monensin, the cell-bound fluorescence intensity was restored reaching 9.1 ± 0.5 (120 + 
3 min monensin). In case of differentiated cells, the MFI values declined from 5.7 ± 0.4 
(0 min) to 3.2 ± 0.2 (120 min) and re-equilibrated to 5.9 ± 0.2 (120 + 3 min monensin) 
upon addition of monensin. Chase incubation at 4°C yielded stable MFI values for both 
untreated and differentiated cells. 
In contrast, cell binding of BSA-conjugated nanospheres was not observed. The pulse 
incubation yielded MFI values of 0.1 ± <0.1 (untreated cells) and 0.2 ± 0.1 (differentiated 
cells) which are only marginally higher than the autofluorescence of the cells. 
Additional information concerning the uptake of WGA-functionalized nanoparticles to 
untreated and differentiated THP-1 cells was collected via fluorescence microscopy. As 
illustrated in Fig. 5 for differentiated cells, control samples incubated with WGA at 4°C 
revealed merely a fluorescent ring of particles around the cells indicating surface binding 
without any signs of internalization when the focus plane was set to the middle of the 
cell. In contrast, after incubation at 37°C a dot-like pattern of fluorescence around the 
nucleus (black spot) was observed pointing to uptake and vesicular enrichment of 
initially surface bound particles. For untreated cells, similar images were acquired (data 
not shown). 
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Discussion 
In this study a systematic characterization of the glycosylation pattern of untreated and 
PMA treated THP-1 cells was performed via detailed analysis of the binding capacities of 
selected lectins in order to investigate possible changes in course of the differentiation 
process. Additionally, the potential applicability of the applied lectins for drug delivery 
purposes at both stages was elucidated. For untreated as well as for differentiated THP-1 
cells, the highest binding capacity was found for WGA, a lectin specific for N-acetyl-D-
glucosamine and sialic acid structures. Regarding the MFI values at 100 pmol, no 
significant difference (p>0.05) between both cell types was detected. STL was the 
second-best binding lectin for both untreated and differentiated cells, which also 
recognizes N-acetyl-D-glucosamine residues. In contrast to WGA, STL-binding was 
significantly differed between PMA-pretreated and non-treated cells over the whole 
concentration range tested. This decrease in N-acetyl-D-glucosamine residues might be 
attributed to an increase of sialic acid moieties present at the cell surface of differentiated 
cells as indicated by the binding rate of SNA, a lectin which specifically binds to α2,6-
linked sialyl groups and yielded a higher binding capacity in case of differentiated THP-1 
cells too (p<0.01). Significant differences in the lectin binding pattern were also observed 
for PNA and LCA. In case of untreated cells, galactosamine residues were assessed via 
PNA, whereas differentiated cells only showed a PNA-binding scarcely above the 
autofluorescence. In contrast, binding of LCA to mannose structures was very low in 
case of untreated cells, whereas PMA-treated cells revealed a notedly higher density of 
mannose at the cell surface. Accessible fucose residues, traceable via UEA, and N-acetyl-
D-galactosamine moieties, being detectable with DBA, were neither found on monocytes 
nor on monocyte-derived macrophages.  
Sabri et al. [7] demonstrated that increased adhesiveness of stimulated THP-1 cells 
resulted in decreased cell coat thickness presumably most affecting O-linked 
carbohydrates. Since Galß1-3-GalNAc represents the core 1 structure of the O-linked 
chains and is detected by PNA-binding, the loss of PNA-binding capacity upon 
differentiation of THP-1 cells to macrophages confirms the aforementioned observation 
Additionally, PMA-differentiation also had an effect on N-linked sugar residues. Among 
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the motifs on N-linked oligosaccharides, α2, 6-linked sialyl groups detectable by SNA 
and trimannosyl core groups detectable by LCA are present. For both lectins a significant 
higher binding capacity was determined on differentiated cells as compared to untreated 
ones (p<0.01) which might be due to upregulation of the CD14 receptor expression 
during differentiation. CD14 posesses four potential N-linked glycosylation sites with a 
carbohydrate content contributing to 20% of the total molecular mass [18]. Thus, 
increased binding of SNA and LCA might occur via these partial structures.  
For targeting approaches, not only a high binding rate, but also the specificity of the 
interaction is an important parameter. Thus, specificity of lectin binding was ascertained 
yielding inhibition values of at least 85% for each individual lectin. 
Uptake of the targeter, a favourable feature in targeted drug delivery, was observed for 
WGA. For this lectin, the enhancement of the phagocytic and bactericidal activity had 
been demonstrated with murine macrophages [15]. In our studies, WGA displayed a high 
binding capacity together with a high specificity for both untreated and differentiated 
THP-1 cells. In case of a selective approach towards either monocytes or macrophages, 
LCA might be a suitable candidate, as this lectin exclusively interacted with 
differentiated THP-1 cells. On the contrary, PNA appears to be useful to target 
monocytic cells. However, according to a study with murine peritoneal macrophages, this 
lectin diminished the phagocytic activity suggesting that O-glycosylation is altered 
during activation of the cells [19]. This observation correlates with our results and thus, 
the application as a drug targeter is questionable.  
The cellular fate of WGA was investigated over a period of 4 h at 4°C and 37°C, 
respectively. As shown in Fig. 5 the incubation temperature exerted a significant 
influence on the MFI values: upon chase incubation at 4°C they remained constant 
indicating an irreversible binding without any evidence for detachment or internalisation 
of the cell-bound lectin. In contrast, at 37°C the fluidity of the cell membrane increases 
and active transport processes can occur. Regarding the MFI values of WGA at this 
temperature, the observed continuous decrease points to internalisation of the lectin and 
enrichment within acidic compartments, since the fluorescence emission of fluorescein is 
known to be reduced at acidic pH. Thus, monensin, a carboxylic ionophore which can 
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compensate the pH-gradient between the cytoplasma and acidic compartments was added 
to the cells to verify this assumption. After monensin treatment the MFI could be re-
established and underlines the obviously pH-dependent and reversible quench of the 
acid-sensitive label (Fig. 5). As analyses of the supernatants yielded no detached WGA, 
calculation of the fraction of WGA entering the lysosomal pathway was possible [20]. In 
case of untreated THP-1 cells, about 15% of the surface bound WGA were accumulated 
after 10 min, in case of differentiated 25%. The cytoinvasion of WGA at the end of 
incubation after 240 min amounted to 64% in case of untreated THP-1 cells and 74% in 
case of differentiated THP-1 cells, respectively. These results indicate that PMA 
treatment of THP-1 cells might elicit a faster and higher phagocytic activity. 
Nevertheless, for both cell types a high internalization rate was assessed and thus, WGA 
seems to be an appropriate candidate for targeting drug carriers to differentiated as well 
as non differentiated cells. 
Moreover, not only uptake of free WGA was observed, but also internalization of WGA-
functionalized PLGA nanoparticles of about 160 nm in diameter. Again, incubation at 
4°C revealed stable MFI values, whereas incubation at 37°C resulted in a decrease in 
cell-associated fluorescence intensities by time which could be restored upon addition of 
monensin. Regarding untreated cells, after 120 min about 40% of the surface bound 
WGA-grafted particles were internalized and subject to reversible pH quenching. 
Regarding differentiated cells, at the same time about 55% were taken up into acidic 
compartments. For comparison, the cell binding of BSA-grafted nanoparticles was 
assessed, but only marginal cell binding could be observed for both cell types. 
Cytoinvasion of WGA-functionalized PLGA nanoparticles was additionally confirmed 
by fluorescence microscopy (Fig. 5). The images acquired after incubation at 37° 
revealed that the staining of the cytoplasm was not uniformly but in a dot-like manner 
indicating vesicular accumulation of the particles. Thus, functionalisation of nanocarriers 
with WGA can lead to enhanced particle uptake into THP-1 cells. This specific 
interaction might be exploited for lectin-mediated targeting of drug delivery systems to 
combat infectious diseases evoked by parasites (malaria, leishmaniasis), facultative 
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intracellular bacteria (brucella, listeria, shigella, mycobacteria) and viruses such as HIV 
which are known to colonize in the mononuclear phagocyte system  [21,22].  
In summary, the glycosylation pattern of THP-1 cells showed significant changes due to 
differentiation with PMA demonstrating a re-organization of sugar residues at the cell 
surface. Additionally, the endocytic capacity to free WGA and WGA-functionalized 
nanoparticles was higher in case of PMA treated cells as compared to untreated cells, 
which might be a result of this rearrangement [4]. In this context, also the potential of 
WGA as a targeting vehicle was evaluated. Following on from this work, the application 
of WGA-grafted drug delivery systems might be an interesting approach towards 
treatment of diseases involving monocytes and macrophages which should be further 
pursued.  
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Tables 
Table 1 
Specificity of the lectins used in the competitive binding assays 
 
Lectin 
 
MW 
 
     Carbohydrate specificity 
 
Inhibitory sugar 
Sugar [c] in µmol/reaction 
(untreated/differentiated) 
WGA  36 000  GlcNAc, sialic acid  N‐acetyl‐D‐glucosamine, 
Chitotriose 
0.004‐0.125/ 
0.004‐0.125 
STL  100  000  GlcNAc  N‐acetyl‐D‐glucosamine, 
Chitotriose 
0.004‐0.125/ 
0.004‐0.125 
PNA  110 000  ß‐D‐Gal‐D‐GalNAc, ß‐D‐
GalNAc, Gal 
D‐galactosamine  0.031‐1/n.d. 
DBA  120 000  α‐D‐GalNAc, Gal  N‐acetyl‐D‐galactosamine  n.d./n.d.   
UEA‐I  63 000  α‐L‐Fuc  L‐fucose  n.d./n.d. 
SNA  150 000  Sialic acid α(2,6)Gal/GalNAc  ‐  n.d./n.d. 
LCA  49 000  α‐Man, α‐Glc, α‐GlcNAc  D‐mannose  n.d./1‐32 
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Figures 
 
 
Fig. 1 
Lectin binding to undifferentiated THP-1 (A) and differentiated THP-1 cells (B) at 4°C. 
The fluorescein-labeled lectins associated with the cell surface were related to an 
apparent F/P ratio of 1 (mean ± SD, n=3). 
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Fig. 4 
Mean cell-associated fluorescence intensities of WGA-loaded differentiated THP-1 cells 
prior and after monensin addition during incubation (0-240 min) at both 4°C and 37°C 
(mean ± SD, n=3).  
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Fig. 5 
Fluorescence microscopy images of differentiated THP-1 cells incubated with WGA-
functionalized PLGA nanoparticles for 120 min at 4°C (A) and 37°C (B). Scale bar 
represents 10 µm 
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4 Conclusion 
 
The present thesis concentrates on the application of plant lectins as tools for the 
analysis of the carbohydrate composition of the glycocalyx and the feasibility of lectin-
mediated drug delivery for various cell types.  
 
Part I focuses on targeted drug delivery strategies for bladder cancer. In this context, 
lectins were applied to 5637 cells as a model for human urinary carcinoma (grade II) to 
estimate the potential and applicability for lectin-mediated targeting. Analyses of single 
cells as well as monolayers grown for several time intervals pointed to a predominance 
of N-acetyl-D-glucosamine structures accessible via WGA. Thus, the cytoinvasive 
properties of this lectin were further investigated for bladder tissue. Results revealed 
accumulation of WGA within acidic compartments and uptake of 50% of the cell-
associated lectin after 10 min in case of single cells and after 4 h in case of monolayers. 
Following on, the cytoadhesive effects of WGA are expected to enhance the therapeutic 
effect of a cytostatic agent after instillation due to prolonged local action counteracting 
the loss of drug by urinary excretion.  
 
These improvements are also part of the general motives for a variety of approaches to 
combat bladder cancer, which were summarized in a review about bladder cancer 
therapy. In course of this review two main concepts were discussed: therapies with 
focus on molecular targets (“targeted therapy”) and “controlled delivery”, a term which 
was used for all other methods for improved drug delivery. After evaluating the existing 
strategies, in our opinion, the future is seen in “smart” drug delivery systems such as 
nanoparticles that contain cytotoxic agents in their core and are decorated with a 
corona of biologicals which guarantee the specific targeting. 
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Part II deals with the characterization of the glycosylation pattern of chondrocytes and 
resulting perspectives for the use of lectins in cartilage research. In the first paper, the 
affinities of lectins for carbohydrate structures at the surface of human chondrocytes 
were assessed using single cells of the human chondrocyte cell lines C-28/I2 and T/C-
28a2. The results revealed lower lectin binding rates on T/C-28a2 as compared to C-
28/I2 which correlates with the observation that T/C-28a2 cells proliferate faster than 
the C-28/I2 clonal line and therefore show less expression of cartilage matrix 
components. Nevertheless, for both cell lines, a remarkable cytoadhesion of WGA was 
observed followed by the conclusion that WGA might be useful for mediating 
bioadhesion to low-adhesive scaffolds in cartilage tissue engineering approaches. Due to 
its cytoinvasive properties, which were also assessed in this study, another possible field 
of application is seen in the preparation of WGA-functionalized drug delivery systems. 
 
As lectins could be successfully administered to C-28/I2 and T/C-28a2 cells, the 
respective work was the basis for the second paper. This time, the main focus was set 
on the evaluation of the glycoprofile of primary human chondrocytes and an additional 
comparison with the two cell lines in order to figure out the contribution of the 
chondrocyte glycocalyx to matrix assembly and alterations of the chondrocyte 
phenotype. Using real-time PCR, immunofluorescence, and glycosaminoglycan (GAG) 
staining, the accurate chondrocytic phenotype of primary chondrocytes was 
characterized by high expression of extracellular matrix genes and proteins, as well as 
GAG and sulfated GAG structures, whereas for the immortalized cell lines a reduced 
chondrocytic phenotype was determined. Analysis of the glycosylation pattern via 
selected lectins showed reduced levels of high-mannose type and sialic acid-capped N-
glycans as well as increased fucosylated O-glycosylation products for C-28/I2 and T/C-
28a2 cells. Thus, alterations of the chondrocytic phenotype were also reflected in the 
glycophenotype of the cells pointing to a significant role of the latter in chondrocyte 
differentiation. 
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In part III the elucidation of the lectin-binding pattern of brain microvascular endothelial 
cells was of particular interest. In the first study, two blood-brain barrier (BBB) 
mimicking cell lines, namely porcine PBMEC/C1-2 and human ECV304 cells, were 
cultured in PBMEC medium (50% C6 medium and 50% astrocyte conditioned medium 
(ACM) of glioma cell line C6), and the bioadhesive properties of selected lectins were 
assessed using monolayers as well as single cells. Comparison of the results with data 
from primary endothelial cells and cortical brain sections revealed that PBMEC/C1-2 
monolayer cultures appear as an appropriate model for lectin-interaction studies. As to 
ECV304 cells, the lectin-binding ranking rested stable for single cells as well as 
monolayers grown for 4 and 14 days. However, due to an increased binding of UEA-I 
during cultivation, a lectin proposed for the characterization of endothelial cells, the use 
of ECV304 monolayers seems to be more suitable. To evaluate the impact of lectins for 
drug targeting purposes, the uptake of WGA and DBA into PBMEC/C1-2 cells was 
monitored. For ECV304 cells, WGA was estimated to be a suitable targeting vehicle due 
to its high binding capacity combined with a high binding specificity. For both lectins, the 
cell association rates were dependent on the temperature indicating cellular uptake. 
 
As lectin-binding has shown to be changed after alterations of the blood-brain barrier 
functionality, the influence of culture conditions on the lectin-binding pattern of the two 
cell lines was investigated in the following study. Astrocytes, astrocyte conditioned 
media (ACM), glioma cells, and glioma conditioned media (GCM) can induce several 
specific blood-brain barrier properties in endothelial cells including increased tightness 
and expression of specific enzymes and receptors. Thus, a possible influence of GCM 
derived from glioma cell line C6 on the lectin-binding capacity was determined. 
PBMEC/C1-2 cells were cultured in basal C6 medium and PBMEC medium as described 
above, whereas ECV304 cells were grown in basal ECV304 medium and ACM of 
ECV304 medium. As significant differences were detected for both cell lines after 
cultivation in GCM, modulation of the carbohydrate composition on the surface of 
blood-brain barrier mimicking cell lines by soluble factors derived from C6 cells was 
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suggested. Ongoing from these findings, the influence of the microenvironment on the 
glycocalyx of the blood-brain barrier and its role during BBB altering or damage are 
supposed to be important parameters. 
 
 
In part IV the glycosylation patterns of untreated and differentiated monocytic human 
THP-1 cells were investigated in order to provide a basis for lectin-mediated targeting to 
these cell types. Significant changes of the lectin binding capacities before and after 
treatment of the cells with phorbol 12-myristate 13-acetate (PMA) pointed to a re-
organization of the glycoconjugates present at the cell surface during differentiation. 
However, WGA yielded the highest binding rates for both cell types without significant 
differences and was therefore chosen for further studies concerning cytoinvasion of 
soluble WGA. After 4 h high uptake rates of 64% and 74% of initially surface-bound 
lectin entering the lysosomal pathway were assessed for untreated and differentiated 
cells, respectively, leading to the preparation of WGA-functionalized PLGA-
nanoparticles. Again, high uptake rates were observed, and a comparison with BSA-
grafted particles, which did not exhibit feasible binding rates, demonstrated again the 
potential of WGA as targeting vehicle to monocytes/macrophages due to the specificity 
of the lectin-cell interaction.     
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In summary, the present thesis outlines the potential of certain plant lectins to detect 
and study the carbohydrate composition at the surface of several cell lines. The 
presented results allow an estimation of the glycosylation pattern of the cell coat and 
reveal possible alterations due to differentiation, different cell culture types, and media 
composition. On the basis of the binding assays and continuative studies concerning 
cytoinvasion, the feasibility of the lectin-mediated targeting concept could be confirmed 
providing a sound basis for future in-vivo studies. 
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5 Appendix 
 
German abstract – Kurzfassung 
Eukaryotische Zellen besitzen an der Außenseite ihrer Zellmembran einen 
Kohlenhydratsaum, die sogenannte Glykocalyx, die je nach Zelltyp aus unterschiedlichen 
Polysacchariden besteht. Neben Proteoglykanen sind diese in der Zellmembran über 
kovalente Bindung an Membranproteine oder Membranlipide verankert und können von 
biorekognitiven Proteinen wie Lektinen erkannt werden. Aufgrund dieser Fähigkeiten 
eignen sich Lektine zur Charakterisierung von Glykosylierungsmustern, die sich im Laufe 
der Entwicklung und Differenzierung, besonders aber auch im Rahmen einer malignen 
Transformation der Zellen verändern können. In der vorliegenden Dissertation wurden 
daher verschiedene Lektine pflanzlichen Ursprungs mit unterschiedlichen 
Zuckerspezifitäten ausgewählt und deren Interaktion mit folgenden Zelllinien untersucht: 
humane 5637 Zellen für Studien am Blasenkarzinom, humane C-28/I2, T/C-28a2 und 
primäre humane Chondrozyten für Knorpeluntersuchungen, porcine PBMEC/C1-2 und 
humane ECV304 Zellen für die Charakterisierung der Blut-Hirn Schranke und humane 
THP-1 Zellen als Modell für Monozyten, die die Fähigkeit besitzen zu Makrophagen zu 
differenzieren. Da einige dieser Zelllinien erst im Zuge der Dissertation in der 
Arbeitsgruppe etabliert wurden, lag ein Hauptaugenmerk auf einer detaillierten 
Charakterisierung dieser Zelllinien, um in Zukunft zuverlässige Ergebnisse zu erhalten. 
Nach Evaluierung der bioadhäsiven Eigenschaften der eingesetzten Lektine sowie der 
Charakterisierung der Bindungsspezifität sollte überprüft werden, ob und in welchem 
Ausmaß Lektine in die Zellen aufgenommen werden. Dieser Aspekt ist bei einem Einsatz 
von Lektinen als „targeter“ für eine gezielte Pharmakotherapie von großer Bedeutung. In 
weiterer Folge wurden daher auch Weizenkeimagglutinin (WGA)-funktionalisierte 
Nanopartikel hergestellt und deren Aufnahme in THP-1 Zellen untersucht, wobei ähnlich 
wie für WGA alleine hohe Einbauraten erzielt werden konnten. 
Zusammenfassend lässt sich festhalten, dass die vorliegenden Ergebnisse eine primäre 
Bewertung des Glykosylierungsmusters der untersuchten Zelllinien erlauben und die 
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prinzipielle Eignung eines Lektin-vermittelten Targetingkonzeptes aufzeigen, sodass diese 
Arbeit eine Grundlage für weiterführende in vivo-Studien darstellt. 
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